Testing for HER2 positive breast cancer. Challenge for improvement of current conditions and practice by Korencan, A. et al.
Testing for HER2 Positive
Breast Cancer 
Challenge for Improvement of
Current Conditions and Practice 
Assessment
LBI-HTA Project Report Nr.: 008
ISSN-Online: 1992-0496 

 Testing for HER2 Positive 
Breast Cancer 
Challenge for Improvement of Current 
Conditions and Practice 
 
 
Assessment 
 
Vienna, June 2007 
Project Management: Dr. Claudia Wild 
Authors: DDr. Andrea Korencan 
with methodical support from Rosemarie Felder-Puig, MSc 
Literature search and documentation: Mag. Beate Guba, MSc 
 
 
 
 
CONTACT INFORMATION
Publisher: 
Ludwig Boltzmann Gesellschaft GmbH 
Operngasse 6/5. Stock, A-1010 Vienna 
http://www.lbg.ac.at/gesellschaft/impressum.php 
Responsible for Contents: 
Ludwig Boltzmann Institute for Health Technology Assessment (LBI-HTA) 
Garnisongasse 7/20, A-1090 Vienna 
http://hta.lbg.ac.at/ 
The HTA project reports of the LBI-HTA do not appear on a regular basis and serve to publicize the 
research results of the Ludwig Boltzmann Institute for Health Technology Assessments. 
The HTA project reports are available in a minimal amount in print and also accessible to the public 
via the Internet at “http://eprints.hta.lbg.ac.at”: 
LBI-HTA Project Report Nr.: 008 
ISSN: 1992-0488 
ISSN-online: 1992-0496 
http://eprints.hta.lbg.ac.at/view/type/1_hta_report.html 
© 2007 LBI-HTA – All rights reserved 
LBI-HTA | 2007 3 
Content 
 Executive Summary............................................................................................................................................. 5 
 Zusammenfassung ............................................................................................................................................... 7 
1 Policy and Research Question.......................................................................................................................... 11 
2 Methods: Literature Search and Selection..................................................................................................... 13 
3 Introduction to HER2 Testing......................................................................................................................... 15 
3.1 Terminology & HER2 Mechanisms .......................................................................................................... 15 
3.2 Tumour Characteristics ............................................................................................................................. 15 
3.3 Relevance of Testing HER2 Status ........................................................................................................... 18 
3.4 HER2 Testing Methods.............................................................................................................................. 19 
3.4.1 Immunohistochemistry (IHC)..............................................................................................................20 
3.4.2 Fluorescence in Situ Hybridization (FISH)........................................................................................21 
3.4.3 IHC and FISH ........................................................................................................................................22 
3.4.4 Fluorescence Immuno Histo Chemistry (FIHC) ...............................................................................23 
3.4.5 Chromogenic In Situ Hybridization (CISH) ......................................................................................23 
3.4.6 Polymerase Chain Reaction (PCR)......................................................................................................23 
3.4.7 Enzyme-Linked Immunoabsorbent Assay (ELISA) ..........................................................................24 
4 HER2 Testing: Validity and Reliability ......................................................................................................... 25 
4.1 Critical Appraisal of Meta-analysis on IHC & FISH............................................................................... 25 
4.2 Conclusions from Meta-Analysis .............................................................................................................. 30 
5 HER 2 Testing: Key Issues ............................................................................................................................... 31 
6 Summary & Conclusion .................................................................................................................................... 39 
7 Excursus: Interpretation for Austria............................................................................................................... 41 
8 Recommendations.............................................................................................................................................. 43 
9 References............................................................................................................................................................ 45 
 Appendix ............................................................................................................................................................. 51 
 Search in Databases.................................................................................................................................... 51 
 Glossary ....................................................................................................................................................... 56 
 
 
List of Figures 
Figure 2-1: Literature selection.......................................................................................................................................14 
Figure 3-1: Proposed mechanism of action of trastuzumab Nahta et al. Cancer Letters 232 (2006)......................16 
Figure 3-2: Procedure for Determining HER2 Status (own presentation) ................................................................18 
Figure 3-3: Patterns of chromosome 17 alterations detected by FISH (PathVision)  
Breast cancer Vol. 13 No 2006 .....................................................................................................................21 
Figure 3-4: Algorithm for determining HER2 status ...................................................................................................22 
 
Testing for HER2 Positive Breast Cancer 
4 LBI-HTA | 2007 
List of Tables 
Table 1-1: Results of trastuzumab trials, comparison 1................................................................................................11 
Table 1-2: Results of trastuzumab trials, comparison 2................................................................................................11 
Table 4-1: Studies in meta-analysis taken from Dendukuri ........................................................................................25 
Table 4-2: Sensitivity and specificity of different IHC and FISH tests, taken from Press et al., 2002 ...................26 
Table 4-3: Results on IHC and FISH sensitivity and specificity by Press et al., 2002..............................................26 
Table 4-4: Results on IHC and FISH sensitivity and specificity by Bartlett et al., 2001 in Dendukuri.................27 
Table 4-5: Correlation D-FISH/S-FISH, Lal et al., 2000 .............................................................................................28 
Table 4-6: HER2 amplification of 2+, Lal et al., 2004 .................................................................................................28 
Table 4-7: IHC/FISH sensitivity taken from Ogura et al., 2004..................................................................................29 
Table 4-8: Results of Meta-Analysis (%).........................................................................................................................30 
Table 5-1: Tumor characteristics and HER-2 status Killeen et al., 2006, page 101...................................................33 
Table 5-2: Comparison of two IHC Tests (2+, 3+ positive cases) Ainsworth et al., 2005 [28] ...............................34 
Table 5-3: Intra-laboratory Interpretation of Repeated Equivocal/Borderline Cases,* taken from [69] ................35 
Table 7-1: FISH diagnostic in Austria (Jan 2007) .........................................................................................................41 
Table 7-2: IHC/FISH sensitivity ([18], [16], [32], [50], [49], [51], [12], [28], [64], [85], [47]) .................................42 
 
 
 LBI-HTA | 2007 5 
Executive Summary 
Background: Breast cancer is the most frequent cancer of women. In some 
breast cancers, the HER2 gene is amplified and over expressed. Patients with 
HER2 positive tumours have poorer prognoses than other types of breast can-
cer. The role of HER2 as a prognostic and therapeutic biomarker has been 
discussed for the past years. Extensive media converage has publicized the 
availability of a targeted therapeutic antibody (trastuzumab) for HER2 posi-
tive tumours. In turn, public demand for this treatment has increased along 
with pressure for the reimbursement of costs associated with it.  
The current use of trastuzumab for patients with metastatic cancer as well as 
those receiving adjuvant therapy highlights the importance of HER2 analy-
sis. The ability to reliably identify patients who might benefit from trastu-
zumab treatment is not only important for clinical reasons such as positive 
clinical effects as well as the possibility of severe adverse events like grade 3 
or 4 cardiotoxicity – but also for economic ones as well. The cost of treat-
ment is currently – about 42,000.– Euros per treatment.  
Whether HER2 expression can predict the response to antibody therapy, 
however, remains controversial and continues to be discussed in many stud-
ies. Recent estimates suggest that approximately 20% of current HER2 test-
ing may be inaccurate. 
Policy and Research question of assessment:  
PQ: Are resources allocated to treat HER2 patients being used in the most 
efficient way? 
RQ: What is the gold standard for diagnosing HER2 positive tumours? Which 
is the most accurate and reproducible method to identify candidates for po-
tential therapy with monoclonal antibodies, and are the applied tests reliable 
for selecting HER2 positive patients? Is it necessary to look closer at specific 
areas of uncertainty – if so, which areas? 
Method: This assessment report is based on a literature search in various da-
tabases (Medline, EmBase etc.) and includes studies (n=75) published after 
the year 2000. The main focus was on the questions of validity, standardiza-
tion and/or calibration of the two most commonly used methods IHC (im-
muno histochemistry) and FISH (fluorescence in situ hybridization), further-
more the inter-observer and the inter-laboratory concordance, and the role 
of the morphological variables and borderline test results.  
Results: The review discusses – systematically – the HER2 testing results of 
more than 23,000 specimens, achieved in local, central or reference laborato-
ries, explored by different testing methodologies at the DNA, RNA and pro-
tein level.  
b Many studies are not comparable, because of differences in number of 
included specimen, the art of tissue extraction, histology of the specimen, 
and used test-methods.  
b IHC results show much greater variability than FISH – test results, par-
ticularly for the FISH negative cases. The results of most presented stud-
ies indicate that high-level HER2 amplification and an IHC score of 3+ 
will identify HER2 positive breast carcinoma; the low-level amplification 
and/or IHC score of 2+ should be carefully interpreted.  
HER2: prognostic & 
therapeutic marker 
became importance 
with availability of 
trastuzumab 
reliable HER2 testing for 
accurately identifying 
patient who might 
benefit and for 
avoidance of false 
positive 
identification of areas  
of uncertainty 
literature searches, 
systematic analysis 
data from 23,000 
specimen but analysed 
by different testing 
methods 
high-level HER2 
amplification and an 
IHC score of 3+  
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b There is agreement that the most (cost-) effective testing strategy is to 
screen all patients with IHC, followed by FISH for IHC of 2+ (or of 2+ 
and 3+). 
b The challenge in routine practice is the differences that exist in the inter-
pretations of probes. Adherence to strict guidelines and instructions for 
handling disconcordant results and validation with clinical results are 
needed. 
b Uncertainty exists on the clinical significance of low level gene amplifi-
cation concerning the response to trastuzumab. The target for trastuzu-
mab is the protein and the gene is only the surrogate marker of the true 
target. 
b Findings concerning different results from local/central laboratories point 
to moderate inter-observer and inter-laboratory reliability of test results. 
A volume/experience relationship is observed.  
b Inter-laboratory comparisons and performance evaluations are important 
in overcoming test limitations. Based on the results of this assessment, 
there seem to be less HER2 positive women than generally reported in 
clinical treatment studies: not 20–30%, but rather 15–20% are amplify-
ing HER2 positive in “real life” settings. 
Conclusion: Although more than 23,000 patients (specimen) have been re-
viewed in the seventy-five studies published in recent years, many unsolved 
questions remain. From a societal perspective, the diagnostic performance of 
the test used to identify trastuzumab candidates has considerable influence 
on cost-effectiveness – independent of test cost – due to the high cost of 
treating patients with false-positive test results and the inability of patients 
with false-negative results to benefit from trastuzumab. Increased efforts in 
accurate testing results might lead to less trastuzumab treatments associated 
with clinical important adverse events: less might be more.  
Recommendation: The following recommendations are extrapolated from the 
results of this review: 
b Due to the high variability between the different IHC-tests, we recom-
mend using only standardized and approved tests. 
b Due to the consequential costs (non-monetary costs/side effects of therapy 
and monetary costs), we recommend to establish SOPs/ standard operat-
ing procedures. 
b Due to high inter-laboratory variabilties, we recommend using a small 
number of reference centers rather than decentralised testing locations 
with lack of routine. 
b Due to high inter-laboratory variabilties, we recommend national and in-
ternational inter-laboratory exchange on results of diagnostic outcome. 
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Zusammenfassung 
Hintergrund: Brustkrebs stellt die häufigste Form der bösartigen Erkrankun-
gen der Frau dar. Bei einem Teil der Patientinnen wird das HER2 Gen am-
plifiziert und überexprimiert. HER2 positive Tumore haben eine schlechte-
re Prognose. Die Rolle des Transmembranrezeptors HER2 als prognostischer 
und therapeutischer Biomarker wurde in den letzten Jahren viel diskutiert 
Die Verfügbarkeit einer zielgerichteten Antikörpertherapie (Trastuzumab) bei 
HER2 positiven Tumoren führte zur enormen Medienpräsenz und steigerte 
die allgemeine Nachfrage sowie den Rückerstattungsdruck. 
Die Anwendungsmöglichkeiten von Trastuzumab macht klar, wie wichtig die 
HER2 Bestimmung ist. Die Möglichkeit, Patientinnen, die durch die Tras-
tuzumab Behandlung profitieren könnten, verlässlich zu identifizieren, ist 
nicht nur aus klinischer Sicht wichtig – positive Beeinflussung des klinischen 
Verlaufs (begleitet allerdings von kardiotoxischen Nebenwirkungen Grad 3 
oder 4) – sondern auch aus ökonomischer Sicht: hohe Behandlungskosten von 
ca 42.000.– Euro pro Behandlung sind zu veranschlagen.  
Ob die HER2 Überexpression die Ansprechbarkeit auf die Antikörperthera-
pie definitiv voraussagen kann, bleibt strittig, und ist Diskussionsthema in 
zahlreichen Studien. Schätzungen zufolge dürften ca. 20 % der gängigen HER2 
Testungen ungenau sein. 
Gesundheitspolitische und Forschungsfrage des Assessment: 
GF: Werden die Ressourcen, um HER2 Patientinnen zu behandeln, auf effi-
ziente Art und Weise angewandt bzw. zur Verfügung gestellt? 
FF: Was ist der Goldstandard bezüglich Diagnostik der HER2 positiven Tu-
moren? Was ist die sicherste und am besten reproduzierbare Methode, um 
Kandidatinnen für eine mögliche Therapie mit monoklonalen Antikörpern zu 
detektieren? Sind die angewandten Tests verlässlich bei der Selektion HER2 
positiver Patientinnen? Ist es erforderlich, bestimmte Unsicherheitsareale 
genauer zu betrachten – und um welche handelt es sich hierbei?  
Methode: Die vorliegende Arbeit basiert auf einer Literatursuche in verschie-
denen Datenbanken (Medline, EmBase etc.) und beinhaltet Studien (n=75), 
die nach 2000 publiziert wurden. Das Hauptaugenmerk lag auf Studien zur 
Validität, Standardisierung und/oder Kallibration von den zwei am häufigs-
ten angewandten Methoden IHC (Immunohistochemie) und FISH (Fluores-
zenz In situ Hybridisierung), sowie auf Konkordanz zwischen Untersuchern 
und Labors, sowie der Rolle der einzelnen morphologischen Variablen und 
von „grenzwertigen“ Testergebnissen. 
Ergebnisse: Die vorliegende Arbeit diskutiert systematisch die Resultate der 
HER2 Testung von mehr als 23.000 Proben, welche in lokalen, zentralen oder 
Referenz-Labors verarbeitet und untersucht wurden. Die analytischen Resul-
tate basieren auf Testmethoden, welche auf DNA-, RNA- und Proteinebene 
durchgeführt wurden. 
Die Vergleichbarkeit vieler Studien untereinander ist problematisch einer-
seits aufgrund von unterschiedlicher Anzahl der Proben, Art der Probenent-
nahme, oder der zugrunde liegenden Histologie, andererseits aufgrund der 
Verwendung verschiedener und/oder unterschiedlich durchgeführter Test-
methoden. 
HER2 erlangte als 
prognostischer und 
therapeutischer Marker 
grosse Bedeutung seit 
der Verfu¨gbarkeit von 
Trastuzumab 
verla¨ssliche HER2 
Testung zur pra¨zisen 
Identifizierung von 
potentiell profitierenden 
Patientinnen mit 
Vermeidung falsch 
positiver Ergebnisse  
Identifikation der 
Bereiche mit hohem 
Unsicherheitsfaktor 
Literatursuche; 
systematische Analyse 
Daten von >23.000 
Proben, mittels 
unterschiedlicher 
Methoden analysiert 
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Die mittels IHC erlangten Ergebnisse zeigen viel größere Variabilität und so-
mit mehr Interpretationsmöglichkeiten als die FISH Resultate – speziell wenn 
man die diskrepanten IHC Ergebnisse bei FISH negativen Fällen betrachtet. 
Die Ergebnisse der meisten vorliegenden Studien führen zur Auffassung, dass 
die „high-level“ HER2 Amplifikation und ein IHC Wert von 3+ HER2 posi-
tiven Tumore zu identifizieren vermag; die „low-level“ Amplifikation und/ 
oder ein IHC Wert von 2+ müssen hingegen mit Vorsicht interpretiert wer-
den. 
Übereinstimmung herrscht bezüglich der effektivsten und kostengünstigsten 
Teststrategie: screening aller Patientinnen mittels IHC, gefolgt von FISH für 
die IHC 2+ getesteten Proben (bzw. für jene mit 2+ und 3+ Auswertung). 
Die wesentliche Herausforderung in der Routinetestung stellt die unterschied-
liche Interpretationsmöglichkeit der Patientinnenergebnisse dar. Das Befol-
gen der strikten Anleitungen und Vorschriften für die Bewertung der diskor-
danten Ergebnisse und die Validierung mit klinischen Ergebnissen ist erfor-
derlich. 
Ungewissheit besteht hinsichtlich klinischer Signifikanz der „low-level” Gen-
amplifikation betreffend das dem Ansprechen auf Trastuzumab. Das Angriffs-
ziel für Trastuzumab ist das Protein, und das Gen ist lediglich der Surrogat-
marker des Angriffsziels. 
Untersuchungsergebnisse betreffend unterschiedliche Resultate aus lokalen/ 
zentralen Labors weisen auf eine nur mäßige Übereinstimmung beim Ver-
gleich der Bewerter und der Labors untereinander hinsichtlich Test-Verläss-
lichkeit hin. Beobachtet wurde eine diesbezügliche Beziehung zwischen un-
tersuchter Anzahl/Mengen und Testerfahrung. 
Vergleiche zwischen den Labors untereinander und Evaluierung der Test-
durchführung sind von größter Wichtigkeit, um die Grenzbereiche der Test-
bewertung interpretierbar zu machen. Beruhend auf den Resultaten aus un-
serer Beobachtung scheint es weniger HER2 positive Patientinnen zu geben 
als allgemein aufgrund von klinischen Studienberichten angenommen: nicht 
20 %–30 % sondern eher 15 %–20 % mittels Genamplifikation HER2 positiv 
getesteter Proben sind in „real life“ settings zu finden. 
„high-level“ HER2 
Genamplifikation und 
ein IHC Wert von 3+ 
Herausforderung 
Unterschiede in der  
2+ Bewertung 
unsicherheit bezu¨glich 
klinischer Signifikanz 
von „low-level“ 
Amplifikationen 
inter-observer & inter-
laboratory Variabilita¨t 
mo¨glicherweise weniger 
HER2 positive 
Patientinnen als aus 
klinischen Studien 
hervorgeht 
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Zusammenfassung: Obwohl mehr als 23 000 Patientinnen (Proben) aus den 
75 vorliegenden, in den letzten Jahren veröffentlichten Studien bewertet wur-
den, verbleiben zahlreiche ungelöste Fragen. Gesundheitspolitisch hat eine 
exakte Diagnosestellung in Hinblick auf die Identifizierung der Trastuzu-
mab-Kandidatinnen beträchtlichen Einfluss auf die Kosten-Effektivität, und 
zwar unabhängig von den Test-Kosten selbst – nämlich infolge von hohen 
Behandlungskosten der falsch positiv getesteten Patientinnen. Große Bemü-
hungen bezüglich verlässlicher Testresultate könnten zu weniger Trastuzu-
mab-Behandlungen führen, verbunden mit weniger Nebenwirkungen: weni-
ger könnte auch mehr bedeuten.  
Empfehlungen: Die folgenden Empfehlungen sind aus den Resultaten dieses 
Überblicksbewertung abzuleiten: 
b Wegen der hohen Variabilität unter den verschiedenen – kommerziell er-
hältlichen und individuell modifizierten – IHC-Tests empfehlen wir nur 
die Verwendung von standardisierten, zugelassenen Tests. 
b Wegen der Folgekosten (nicht-monetäre Kosten wie Therapienebenwir-
kungen und real anfallende Kosten) empfehlen wir die Erstellung von 
SOP/Standard operating procedures. 
b Wegen der großen Variabilität beim Laborvergleich empfehlen wir Bevor-
zugung der Zentrallabors/Referenzzentren entgegen der zu beobachten-
den Dezentralisierungstendenz, speziell im Falle der FISH-Diagnostik. 
b Wegen der großen Variabilität unter den testenden Laboreinheiten emp-
fehlen wir verstärkten nationalen und internationalen Austausch über die 
Testergebnisse, sowie externe Evaluation bezüglich Testdurchführung. 
 
 
zunehmende 
Bemu¨hungen bezu¨glich 
verla¨sslicher Diagnostik 
werden die Effekte und 
Kosten fu¨r Trastuzumab 
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Standardisierung, 
Durchfu¨hrungskontrolle, 
Referenzzentren 
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1 Policy and Research Question  
The Human Epidermal Growth Factor Receptor 2 Gene (“HER2”) encodes a 
protein expressed on the surface of breast cancer cells and makes those cells 
more sensitive to growth factors. An over-expression of HER2 can accelerate 
the genesis of tumours and the proliferation of cells. HER2 positive tumours 
have poorer prognoses. Trastuzumab (Herceptin), a recombinant, humanised 
monoclonal antibody that targets the HER2 protein, has been approved for 
metastatic and adjuvant treatment regimes in combination with chemother-
apy. Having only been tested in animal research [1], however, scientists do 
not yet understand exactly how and why the antibody works.  
Currently, trastuzumab is used for the treatment of advanced HER2 breast 
cancer and adjuvant treatment of primary tumours in their early stages. Dif-
fusion of trastuzumab began on the basis of conference presentations before 
it was even officially approved by the EMEA. No critical appraisal of its effi-
cacy and safety had been conducted prior to its broad diffusion under public 
pressure.  
Table 1-1 and Table 1-2 give an overview of the current results of clinical tri-
als on the efficacy and safety of trastuzumab for ARR/ absolute risk reduc-
tion (efficacy) with reduced mortality (Table 1-1) varying from 0.5% to 6.9% 
in the study with the least duration and the absolute risk increase for serious 
adverse events for patients treated with trastuzumab (Table 1-2) varying from 
0% (again the study with the least duration) to 2.8%. A Belgian assessment 
by Huybrechts et al. from 2006 [1] provides a more detailed report of the re-
sults.  
Table 1-1: Results of trastuzumab trials, comparison 1 
Publ. N 
treatment 
duration H®
Follow-up 
(years) 
mortality  
with H® 
mortality 
without H® NNT 
NEJM 2005 [2] 3351 1 year 2 3.7% 5.5% 56 
Abstr. 2005 [3] 2148 1 year 2 1.9% 3.4% 67 
NEJM 2005 [4]  3387 1 year 1 1.7% 2.2% 200 
Lancet 2007 [5] 3401 1 year 2 3.5% 5.3% 56 
NEJM 2006 [6] 231 9 weeks 3 5.2% 12.1% 14 
Source: presentation Felder-Puig 2007 [7] 
Table 1-2: Results of trastuzumab trials, comparison 2 
Publ. N 
treatment 
duration H® 
Follow-up 
(years) 
¾ grade cardial 
events with H®
¾ grade cardial 
events without H® NNH 
NEJM 2005 [2] 3351 1 year 2 3.1% 0.3% 36 (13) 
Abstr. 2005 [3] 2148 1 year 2 2.3% 1.0% 77 (15) 
NEJM 2005 [4]  3387 1 year 1 0.5% 0.1% 250 (18) 
Lancet 2007 [5] 3401 1 year 2 0.6% 0.1% 200 (16) 
NEJM 2006 [6] 231 9 weeks 3 0.0% 0.0% – (8) 
Source: presentation Felder-Puig 2007 [7] 
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The effects of trastuzumab in both the metastatic and the adjuvant setting – 
mostly reported upon in quoting the “reduced relative reduction” in mortal-
ity (ranging from 30% to 79%) has received extensive media coverage and in-
creased the importance of ERBB2 analysis. Clinicians must base their treat-
ment decisions on highly accurate information and precise measurements of 
gene expressions.  
The proportion of HER2 breast cancers decreases with patient age [1] and is 
highest in the youngest patients. These clinical trials often may have had 
more younger than older patients and this could be why the 20–25% (and 
even more) of newly reported HER2 cancers cited in the clinical trials is 
higher than the amount reported in the “real world”. Only 16% of the pa-
tients in the HERA-trial [5] were 60 years or older [8]. Given the relatively 
wide range of possible HER2 positive receptor status in breast cancer patients, 
it is assumed that HER2 diagnostic testing is less sensitive and specific than 
generally anticipated and that a number of patients are recommended need-
less treatments or not recommended necessary treatments because of it.  
The ability to reliably identify patients who might benefit from trastuzumab 
treatment is not only important for clinical reasons (a high proportion of 
grade 3 or 4 cardiotoxicity) – but also for economic ones as well (high treat-
ment costs of about 42,000.– Euros per treatment).  
Using current methods, the ability of positive predictive values (PPV) of the 
receptor status to predict the benefit of trastuzumab treatments is modest 
(25%–40%) [9]. 
This therefore raises a policy question:  
b Are resources allocated to treat HER2 patients being used in the most  
efficient way? 
Related research questions include: 
b What is the gold standard for diagnosing HER2 positive tumours? 
b Are the applied tests reliable for selecting HER2 positive patients? 
b Is it necessary to look closer at specific areas of uncertainty – in which 
areas? 
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2 Methods: Literature Search and Selection 
The aim of the literature search was to identify relevant publications for an-
swering the research questions on testing for HER2 positive breast cancer. 
The following databases were searched: Medline (via Ovid), Embase (via 
Ovid), Pascal Biomed (via Ovid), Cochrane CENTRAL (via Ovid) and Biosis 
Previews (via Ovid). The search strategies are included in Appendix 1. 
Inclusion Criteria: 
b Questions of validity, standardization and/or calibration of FISH or IHC 
b General descriptions of tests: IHC & FISH 
b Other HER2-test methods: serum, RT-PCR, CISH etc. 
b Concordance FISH and IHC, n=>80, Sensitivity, specifity,  
predictive value, n=>80 
b Inter-observer concordance, inter-laboratory concordance 
b “Real-life” findings: central vs. small laboratories 
b Tests with different materials (carcinoma in situ or invasive) 
b Borderline HER2 expression, 2+ HER2 inconsistency & tools to evaluate 
b Inter-observer reproducibility FISH 
b Ring studies of FISH, standards 
b Language English or German. 
Exclusion Criteria: 
b HER2 expression in tumours other than mamma 
b Male mamma carcinoma 
b Radiological diagnostics of carcinoma: HER2 vs. non-HER2 
b Monitoring response to chemotherapeutic schemes 
b Correlation between HER2 status and worse outcome 
b Special subpopulations (pregnant) 
b Testing primary vs. recurrent tissue 
b Findings published before 2000 
b Languages other than English or German. 
 
literature search in 
various databases 
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Figure 2-1: Literature selection 
 
 
references identified 
in literature search  
N=787 
ordered (full text) 
N=107 
included references 
N=75 
excluded references 
N=680 
excluded references* 
N=32 
references on: 
b concordance of results 
FISH & IHC : 23 
b additional histological 
correlations: 13 
b other methods: 13 
 
 
 
 
N=49 
FISH-background 
information on: 
a. inter-observer 
reproducability: 10 
b. discrepancies in 
different materials: 4 
c. handling borderline: 5 
d. quality assurance: 
centralized vs. local 
laboratories: 7 
N=26 
* Excluded after complete control of whole text for not fulfilling inclusion criteria 
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3 Introduction to HER2 Testing 
3.1 Terminology & HER2 Mechanisms 
ERBB2 (human epidermal growth factor receptor 2 gene) is the official name 
provided by the HUGO Gene Nomenclature Committee for the v-erb-b2 eryth-
roblastic leukaemia viral oncogene homolog 2 gene that encodes a member of 
the epidermal growth factor receptor family of receptor tyrosine kinases [10].  
Literature on the gene uses several other names, for example NEU, NGL 
HER2, TKR1, HER2, c-erb B2, HER2/neu. This article refers to the gene by 
the commonly used term HER2. 
The Human Epidermal Growth Factor Receptor 2 gene – ERBB2 – (com-
monly referred to as HER2) is a gene that helps to control how cells grow, 
divide and repair themselves. The HER2 gene provides the blueprint for 
manufacturing the HER2 protein. This protein, which is attached to a cell 
membrane, begins a signalling cascade that regulates normal cell growth. In 
a normal cell producing HER2, there are two copies of the gene and about 
50,000 copies of the protein at the cell surface. The proto-oncogene HER2 
gene resides on the long arm of chromosome 17. Normally, one HER2 gene 
exists for every chromosome 17. However, when a person develops cancer, the 
HER2 gene may create additional copies of itself and becomes “amplified”.  
Many adult tissues, including those of the breast, endometrium, prostate and 
ovary, normally express low levels of a protein encoded with this gene [11]. 
The human HER2 gene encodes one member of a family of transmembrane 
tyrosine kinases (HER1-4), the prototype of which is the epidermal growth 
factor receptor (HER1, ERBB1) [12]. ER-positivity is inversely related to 
HER2 positivity [13]. Too many copies of the HER2 gene can result in the 
over-production, or over-expression, of the HER2 protein receptors found on 
the surface of tumour cells. HER2 over-expression is observed in invasive 
breast carcinomas with poor prognoses. 
To what extent clinicians can use HER2 expression to predict the response 
to hormonal therapy, however, remains controversial and continues to be dis-
cussed in many studies [14]. 
 
 
3.2 Tumour Characteristics 
Morphological variables such as tumour size, grade, and metastases to re-
gional lymph nodes, are important prognostic indicators for breast cancer 
patients. In addition, amplification of HER2 proto-oncogene has been re-
ported to occur in 10%–34% of invasive breast carcinomas [11], or in 20%–
30% [15], 15%–30%[16, 17], 20%–25% [18, 19], or 20%–35%[14] of breast 
cancer tumours, respectively, as well as in up to 80% of DCIS (ductal carci-
noma in situ) [16], and to be of both prognostic and therapeutic significance.  
Molecular markers measured in the tumour or serum provide prognostic and/ 
or predictive information that enables optimization of treatment selection for, 
and management of, breast cancer patients [20]. 
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Figure 3-1: Proposed mechanism of action of trastuzumab 
Nahta et al. Cancer Letters 232 (2006) 
Scientists assume that a correlation exists between HER2 amplification and 
the histological type and grade of breast cancer. A review of the histological 
features and corresponding HER2 amplification results of 401 cases of inva-
sive breast carcinoma support this as well [11]. Clinicians also assume a re-
lationship between HER2 amplification and the type of breast cancer (ie, in-
vasive ductal or invasive lobular) and the Scarff-Bloom-Richardson/SBR grade 
for invasive ductal carcinoma. Of the 401 cases, 388 were diagnosed as inva-
sive ductal, invasive lobular or metastatic breast carcinoma. The remaining 
thirteen included “special type”- tumours, such as tubular, medullary, in-
flammatory, secretory and colloid carcinomas. Of the 388 cases, 300 were in-
vasive ductal, 68 invasive lobular and 20 metastatic tumours. 
Overall, invasive ductal carcinomas were significantly more likely to show 
HER2 amplification than invasive lobular carcinomas. From the invasive 
ductal carcinomas more high grade carcinomas were HER2-positive as com-
pared to low grade [11]. Hoff et al. found – concerning intra-tumoral hetero-
geneity in HER2 copy – a concordance of 100% between the invasive and in-
tra-ductal components in all (14) carcinomas. Data from the study supports 
the association between HER2 amplification and both tumor type and histo-
logical grade of the invasive ductal carcinoma. The authors suggest, that if 
HER2 amplification is present in grade 1 (Scarff-Bloom-Richardson/SBR 
grading) invasive ductal or in invasive lobular carcinomas, a re-examination 
of the morphological features of the neoplasm should be performed to con-
firm tumour type and grade as a matter of quality assurance [11]. 
When and where the oncogene HER2 may interfere in the development of in 
situ and invasive carcinomas remains unclearl. Existing studies support sta-
bility over time – HER2 status would stay the same in the primary breast 
carcinoma and the following metastasis [14]. Andersson et al. [14] investigated 
intratumour HER2 heterogeneity within the invasive component and com-
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pared invasive and in situ components of the same tumour. Seventy-eight 
consecutive invasive breast carcinoma specimens were prospectively evalu-
ated. The material selected was primarily from small tumours. Five percent 
had a strong (3+) and nine percent a moderate (2+) HER2 over-expression.  
When tests were performed using FISH (PathVision), 83% had no amplifi-
cation, 6% a high grade (defined as >10 copies/nucleus) and 8% a low grade 
of amplification (defined as 6 to 10 copies/nucleus). Only one tumour (one 
percent) showed heterogeneity within the invasive component of the tumour 
with respect to HER2 status (as determined by IHC and FISH) within the 
invasive component.  
Both in situ and invasive components existed in forty-eight tumours (62% of 
78 tumours). Twelve of the 48 tumours (25% of those, but 15% of all 78) had 
at least two arbitrary units showing a different HER2 status analyzed by IHC. 
When eight of them were reanalyzed with FISH and IHC; the study found a 
discordance in amplification status between the in situ and the infiltration 
component (FISH negative) in five (6% of 78) of the reanalyzed tumours.  
Andersson et al. [14] conclude that only the invasive component should be 
analyzed. 
The most common combination of histological type in these tumours was in-
vasive ductal carcinoma together with DCIS (ductal carcinoma in situ), fol-
lowed by invasive lobular carcinoma with LCIS (lobular carcinoma in situ), 
tubular carcinoma/DCIS, tubular carcinoma/LCIS, lobular carcinoma/DCIS 
and mucinous carcinoma/DCIS. 
Researchers generally agree that some problems exist regarding the correct 
diagnosis of HER2 status. HER2 expression is not seldomly heterogeneous 
in invasive compared with in situ components within a tumour. Up to 80% 
of DCIS over-express HER2 [16]. The observation that HER2 signalling path-
way activation is more frequent in DCIS versus invasive carcinomas may in-
dicate that HER2 amplification is an early event in the progression of human 
breast carcinoma. Therefore, only the invasive part of a tumour should be 
scored. Due to this, any technique that does not preserve the tissue architecture, 
such as fine-needle aspiration cytology or cytosol-based analyses, becomes a 
less favourable method for evaluation of HER2 status in primary tumours.  
To avoid heterogeneity as a confounding factor in HER2 analyses, detection 
methods such as IHC and FISH, which can provide evaluation in a preserved 
tissue architecture, should be used [14]. 
Ridolfi et al. [21] state that when compared to invasive carcinomas, a higher 
percentage of DCIS cases (up to 55% of high grade DCIS) are HER2 positive. 
A small percentage of invasive breast carcinomas demonstrate HER2 ampli-
fication, but no detectable over-expression. Almost all cases with mixed DCIS/ 
invasive elements exhibited concordant HER2 IHC expression. In four cases, 
the DCIS component showed 3+ membrane staining and the invasive com-
ponent was negative. In two of the cases, the FISH findings were concordant 
with IHC but in the other two, both the DCIS and invasive elements were 
amplified by FISH. A discordance in over-expression was apparent without 
a comparable discordance in amplification by FISH. Dressler et al. [22] men-
tion in the overview on the measurement of HER2 status that protein over-
expression occurs in up to two-thirds of in situ carcinomas.  
Since HER2 over-expression is very common in high-grade, comedo-type 
DCIS, the HER2 status may be useful in determining the invasive potential 
in patients [23]. 
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3.3 Relevance of Testing HER2 Status 
The availability of a targeted monoclonal antibody therapy for HER2 positive 
breast cancer has focused interest on the accurate detection of HER2 status. 
HER2 positivity – amplification of the HER2 and/or overexpression of its pro-
tein – is required for the selection of patients for the therapy. However, re-
searchers do not agree on the best method for determining HER2 status. 
Technical validation of HER2 testing means that the testing assay is sensi-
tive, specific, reproducible, can be interpreted in a relatively uniform manner 
among laboratories and, importantly, that the technical validation has been 
calibrated to clinical outcome [20]. Recent estimates suggest that approxi-
mately 20% of current HER2 testing may be inaccurate [10].  
The definition of optimal algorithm for HER2 testing depends on laboratory 
documentation:  
b Internal validation procedure (25-100 samples tested by alternative 
validated method (in the same lab or in another lab)  
b Internal quality assurance procedure (use of standardised operating 
procedures including routine use of control materials) 
b External proficiency assessment (participation in testing program) 
b Laboratory accreditation. 
 
Figure 3-2: Procedure for Determining HER2 Status (own presentation) 
availability of a targeted 
monoclonal antibody 
therapy 
estimated inaccuracy of 
HER2 testing in 20% of 
patients 
sometimes radiological control 
(because of  
suspicious calcium deposit) 
extraction of specimen 
(fine needle biopsy, surgical resection) 
1
fixation  
(critical time period) 
2
pathological fixation 
(critical time period) 
3
paraffin embedding 
and transection 
4
IHC 
(as specified by manufacturer) 
5
diagnosis 
6
clinical decision 
(therapy) 
7
ev. 2b 
FISH  
(in case of 2+,  
or 2+ and 3+ IHC results) 
ev. 5b 
Introduction to HER2 Testing 
LBI-HTA | 2007 19 
Although specific fixation protocols vary, commonly all specimens (from nee-
dle core biopsies, open or lumpectomy excisions, mastectomies, metastatic 
lesions or unspecified samples) undergo fixation in neutral buffered forma-
lin. 
For inclusion in different studies, the following criteria for specimens should 
be met: previously molecular characterisation for HER2 gene amplification 
(either Southern hybridization or slot/dot blot hybridization using DNA ex-
tracted from breast cancer specimens) and HER2 over-expression assessed by 
either solid matrix blotting of RNA or protein extracted from breast cancer 
specimens (Northern hybridization, dot blot hybridization, and Western im-
munoblot) or IHC. The analyses of amplification and expression should show 
agreement between amplification and expression status. However, the use of 
a wide variety of analytical methodologies for assessing HER2 status has com-
plicated interpretation of results. 
 
 
3.4 HER2 Testing Methods 
HER2 testing methodologies measure HER2 over-expression[20]: 
b At the DNA level by  
b FISH 
b Southern Blot 
b PCR – Competitive 
 – Differential 
 – Real-time 
b At the RNA level by  
b Northern Blot 
b At the protein level by 
b ELISA 
b Western Blot 
b IHC. 
To determine clinical HER2, tissue-based methods, such as IHC analysis and 
FISH have replaced whole-tissue extraction methods, such as Southern Blot 
analysis, enzyme-linked immunosorbent assay, and PCR, which may require 
fresh tissue or suffer dilution owing to admixing of tumour and normal cells. 
A variety of methods are available to assess tissue HER2 status, but for clini-
cal and research purposes, the most widely applied techniques are: 
b ImmunoHistoChemistry (IHC) and  
b Fluorescence in Situ Hybridization (FISH). 
IHC and FISH are performed on sections cut from formalin-fixed, paraffin-
embedded specimens and have emerged as the most frequently employed 
techniques in clinical practice and clinical research [20]. In surgical labora-
tories they easily can be performed according to manufacturer’s specifications. 
The tissue results of the recommended IHC and FISH are not reliable to cor-
relate with the serum HER2 (SHER2) levels. 
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3.4.1 Immunohistochemistry (IHC) 
A protein-based test is used to determine the total amount of HER2 protein 
receptors on the surface of the cell. To do this, the surface of the cell is 
“stained” with an antibody. Over thirty anti-HER2 mouse monoclonal or 
rabbit/goat polyclonal antibodies are available. Scientific literature reports 
more accurate results for testing with R60 Polyclonal Antibody, 10H8 Mono-
clonal Antibody or CB11 Monoclonal Antibody, when previously molecu-
larly characterized. These antibodies are directed towards either the extra-
cellular or intramembraneous domains of the HER2 receptor[20]. A patholo-
gist has to judge the degree of colour change in the cell to determine a HER2 
protein measurement level of 0, 1+, 2+ or 3+.  
IHC scoring method [24]: 0 (negative): no staining is seen, or membrane stain-
ing in less than 10% of tumour cells; 1+ (negative): a faint/barely percepti-
ble membrane staining is detected in more than 10% of tumour cells. The 
cells are only stained in part of the membrane; 2+ (borderline): weak to mod-
erate complete membrane staining is seen in more than 10% of tumour cells; 
3+ (positive): strong complete membrane staining is seen in more than 10% 
of tumour cells. 
IHC can be performed easily on formalin-fixed, paraffin-embedded tissue – the 
form typically preserved by clinical trials – as well as on frozen samples [20]. 
Control slides (to control signal positivity) from cell lines with predetermined 
HER2 expression levels are included and this method is less expensive than 
FISH. 
However some disadvantages exist: Tissue fixation and processing, as well as 
differences in scoring criteria, controls and inter-observer variability in inter-
preting results can all contribute to variability [20]. Fixation protocols, anti-
bodies used and staining procedures influence the success of IHC [25]. Pre-
analytical variables such as tissue-handling and fixation can affect immuno-
reactivity. Researchers studying IHC results using 28 different anti-HER2 
antibodies found marked variability with positive results ranging from 2% to 
30% in the same group of specimens[26]. 
Pathway ..............(Ventana Medical systems, Tuscon, AZ) 
Monoclonal antibody CB-11 is used 
HercepTest .........(DAKO) 
Rabbit polyclonal antibodies are used. 
The Food and Drug Administration (FDA) was the first to approve the Her-
cepTest IHC kit (Dako). Since then, the kit has achieved wide usage and of-
fers a comprehensive protocol, standardized reagents and control slides [20]. 
Later, the FDA also appoved Pathway. For both, a final score of 3+ is con-
sidered positive.  
IHC does not seem to be a reproducible technique as long as there are no 
standardizations of procedure, for example, using the primary antibody NCL-
CB11, because of different methods of immunostaining as well as different 
scoring systems [27].  
Researchers compared CBE356 (not approved) to HercepTest in 167 FISH 
characterised breast carcinoma [28]. IHC was performed using CBE356 mouse 
monoclonal antibody, and HercepTest which is based on polyclonal antibody. 
Sensitivity, specifity, predictive values, and overall accuracy were calculated 
for both IHC methods using gene amplification by FISH as the endpoint. 
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Results showed positive IHC staining for HER2 using CBE356 to be more 
accurate and 23% more sensitive at predicting HER2 gene amplification than 
the other method. 
Because IHC testing lacks accuracy and reproducibility (use of different anti-
bodies, differences in tissue fixation), a FISH test is often performed to con-
firm the results. The main advantage of the IHC assay over FISH is that it is 
faster and more economic to use [29]. Automated cellular imaging (ACIS)™ 
has been able to improve accuracy and reproducibility in IHC scoring, the 
concordance rate between IHC-ACIS (>2.2) and FISH (≥2.0) by PathVysion 
was 94% (247 primary breast cancer cases were studied) [30]. 
 
3.4.2 Fluorescence in Situ Hybridization (FISH) 
 
Figure 3-3: Patterns of chromosome 17 alterations detected by FISH (PathVision) 
Breast cancer Vol. 13 No 2006 
FISH detects amplification of the HER2 gene. It is a gene-based test that 
measures the number of HER2 genes in a cell. The FISH test “highlights” 
the HER2 genes inside the cell, making them appear fluorescent so they may 
be accurately counted. If a patient has more than two genes per cell, the tis-
sue is considered HER2 positive. If the test shows a normal gene count, it is 
considered HER2 negative.  
The FISH is a type of hybridization in which a DNA “probe” is labelled with 
fluorescent molecules so that it can be seen with a microscope. The word “in 
situ” means that the hybridization occurs “in place”, within the nucleus of 
specimen cells that have been fixed to a microscope slide. To conduct a FISH 
analysis, one warms fixed cells mounted on a microscope slide to unwind 
their chromosomal DNA and allow access of the DNA probe. After adding 
the probe, the specimen cells are then cooled to allow the DNA probe to hy-
bridize with its complementary target DNA. Once hybridized, the fluores-
cent molecules on the probe will show precisely where their target DNA lies 
along a chromosome. Depending upon the design of the probe DNA, one can 
detect many types of genetic changes. 
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The procedure is not dependent on the subjective interpretation of the inten-
sity of staining. Although, it is less susceptible to problems associated with 
tissue handling and fixation, the technique is not always feasible in routine 
practice (fluorescence microscopy). Another disadvantage is the need for spe-
cialist equipment, time and skills for interpretation and costs. In a small frac-
tion of cases HER2 – FISH fails to produce interpretable results [31], only 
3.9% of 405 FISH non-informative tumours showed a 3+ IHC result as com-
pared with 12.6% of those with successful FISH. Unspecified tissue damage 
that is impairing the FISH analysis is probably reducing IHC staining. 
Path Vision (Vyses), distributed by Abbott, uses two DNA probes; one spe-
cifically recognizes the HER2 gene and the other is specific for the chromo-
some 17 centromere. Gene and centromere signals are determined in 60 nu-
clei and the HER2 gene: chromosome 17 centromere ratio is calculated. A ra-
tio of ≥ 2 indicates HER2 amplification [20].  
Inform HER2 (Ventana) uses a single probe to measure the absolute number 
of HER2 gene copies. The key difference is the inclusion of a probe for chro-
mosome 17 in the Path Vision assay but not in the Ventana assay [32]. A dual 
probe FISH assay should be used because it can distinguish HER2 gene am-
plification from chromosome 17 polysomys [12]. The standard FISH method 
not only analyzes whether the HER2 gene is amplified but also assesses the 
degree of amplification. The gene dosage phenomenon could have a signifi-
cant role in the spectrum of therapeutic responses [32]. 
 
3.4.3 IHC and FISH 
The two most commonly used methods are IHC and FISH. The current prac-
tice is to consider  
b an IHC score of 0 or 1+ as HER2 negative 
b an IHC score of 2+ as ambiguous 
b an IHC score of 3+ as HER2 positive. 
 
Figure 3-4: Algorithm for determining HER2 status 
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The IHC 2+ category is re-tested by FISH: 
b PathVision (Vyses):  
FISH ratio <2 – non amplified (negative) 
FISH ratio ≥2 – amplified (positive) 
b Inform HER2 (Ventana): Gene amplification is noted as none  
(1–5 copies), low- level (6–10 copies) or high level (>10 copies).  
 
3.4.4 Fluorescence Immuno Histo Chemistry (FIHC) 
A simultaneous detection of HER2/neu gene amplification and protein ex-
pression has been established. Based on four paraffin-embedded breast can-
cer cell lines, a combined fluorescent immunostaining (FIHC) and FISH 
method has been developed by using the PathVision HER2 DNA Probe Kit 
(Vysis) and the polyclonal antibody from the HercepTest (Dako). As a refer-
ence for both gene amplification and protein expression, researchers used four 
breast cancer cell lines. By combining and optimizing individual procedures 
as a multiparametric approach, the new method could be useful in predicting 
outcome of treatment in patients with discordant IHC/FISH results [25]. 
 
3.4.5 Chromogenic In Situ Hybridization (CISH) 
The assay target is the HER2 gene. CISH offers the ability to view morpho-
logical features of the cells analyzed using the traditional brightfield micros-
copy. However, HER2 and centromer 17 are not simultaneously visible using 
CISH. Furthermore, researchers have demonstrated that a small number of 
cases displaying low level amplification by CISH contained chromosome 17 
polysomy by FISH.  
The concordance of CISH and FISH is 96% – 100% in different reported se-
ries [33]. Another study [34] found a concordance between CISH and FISH 
of 95% in 174 assessable cases. Considering FISH as the gold standard, CISH 
has a sensitivity of 97.5% and a specifity of 94%. Reagent costs of CISH are 
about half of those of FISH, but CISH’s superiority has yet to be definitively 
demonstrated. 
 
3.4.6 Polymerase Chain Reaction (PCR) 
PCR is a technique under investigation for the testing of HER2 status, either 
to complement or to substitute other tests. In practice, PCR can fail for vari-
ous reasons. Therefore a number of techniques and procedures have been de-
veloped for optimizing PCR conditions. Quantitative real-time PCR, for ex-
ample, is a homogenous method that includes both amplification and analy-
sis. 
Garcia et al. [33]presented a study where concordance rates between real-time 
PCR and IHC and FISH were 91% and 92%, respectively. Because PCR re-
quires micro-dissection, the author theorizes that any technique not preserv-
ing tissue architecture is less favourable in evaluating HER2 status.  
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The quantitative competitive PCR adds a level of control using an internally 
amplified competitor [35]. A quantitative differential PCR targets the HER2 
gene and a reference gene, enabling calculation of a ratio [36]. Dressler et al. 
[37] discuss the HER2 results of a study comparing IHC, FISH and D-PCR. 
They found only a moderate level of concordance among the three methods 
in assays from 524, 523 and 491 cases, respectively. It seems that none of the 
methods is clearly superior. 
In conclusion, for confirmatory HER2 testing, PCR could be used for inde-
terminate cases. 
 
3.4.7 Enzyme-Linked Immunoabsorbent Assay (ELISA) 
The HER2 gene product is composed of a cytoplasmic domain with tyrosine 
kinase activity, a transmembrane domain and an extracellular domain (ECD). 
The HER2 ECD levels can be detected by ELISA. 
The advantage of this method is that blood is relatively easy to collect. Real-
time monitoring of changes in HER2 status in response to HER2 targeted 
therapies is possible. But ECD levels do not always correlate with the tu-
mour load. 
Many studies show a good correlation between serum levels of HER2 ECD 
and other methods on tissue (IHC and FISH) in metastatic breast cancer [38]. 
Significant higher concentrations of serum HER2 were found in FISH posi-
tive tumours [39]. However, in another study [40], in spite of concordance 
with tissue, HER2 overexpression (85% and 95% respectively) and FISH (83%), 
fifty percent of patients whose disease did not show gene amplification, had 
elevated baseline HER2 ECD levels. The study found no correlation between 
baseline ECD level and likelihood of response to therapy. 
Otherwise, a significant reduction in serum levels predicts improved response 
rates and time to progression [19].  
The method is FDA-approved to monitor response to therapy. 
 
quantitative 
competitive PCR,  
 
quantitative differential 
PCR 
advantage of ELISA 
correlation between 
HER2 ECD and tissue 
methods 
 LBI-HTA | 2007 25 
4 HER2 Testing: Validity and Reliability 
4.1 Critical Appraisal of Meta-analysis on IHC & FISH 
Accurate testing for HER2 in breast cancer can be achieved using IHC with 
complementary FISH testing. 
In 2006, researchers from the McGill University Health Centre [41] presented 
a literature review on the validity and reliability of two commonly used HER2 
testing methods: IHC and FISH. The studies included in the meta-analysis 
show enormous variability. 
Table 4-1: Studies in meta-analysis taken from Dendukuri 
Studies with results reported jointly for IHC 0 and 1+ categories 
Distribution of IHC 
results (%) 
FISH positivity rate (%) 
By IHC score 
Author (Year) N 0.1+ 2+ 3+ 0.1+ 2+ 3+ 
1. Lottner (2005) 215 78.1 11.6 10.2 2.4 72.0 100.0 
2. Loring (2005) 110 56.4 15.5 28.2 0.0 0.0 87.1 
3. Dowset (2003) 426 63.4 12.7 23.9 0.7 48.1 94.1 
4. Press (2002) 117 74.4 11.1 14.5 14.9 100.0 100.0 
5. Bartlett (2001) 210 85.2 10.0 4.8 6.7 90.5 90.0 
6. Hoang (2000) 100 74.0 2.0 24.0 0.0 0.0 70.8 
7. Kakar (2000) 112 70.5 15.2 14.3 1.3 3.5 87.5 
8. Mrozkowiak (2004) † 360 2.8 87.5 9.7 0 20.3 91.4 
9. Yaziji (2004) † 2913 49.0 39.5 11.5 2.8 17.0 91.6 
 
Studies with results reported separately for IHC 0 and 1+ categories 
Distribution of IHC 
results (%) 
FISH positivity rate (%) 
By IHC score 
Author (Year) N 0 1+ 2+ 3+ 0 1+ 2+ 3+ 
10. Lal (2004) 2279 44.6 31.4 13.7 10.3 1.1
2.1 
3.1 
5.7 
26.5 
24.6 
89.7
90.6 
11. Ogura (2003) 110 24.6 47.3 9.1 18.2 3.7 3.8 10.0 100.0 
12. Tsuda ( 2001) 101 41.6 34.7 5.9 17.8 2.4 2.9 0.0 83.3 
13. McCormick (2002) † 198 26.8 29.8 22.7 20.7 3.8 8.5 3.5 87.5 
14. Roche (2002) **, † 119 7.6 8.4 10.1 73.9 0 0 0 89.8 
15. Press (2005) **, † 842 36.5 17.8 36.5 9.3 3.6 5.3 26.5 66.4 
16. Dolan (2005) † 129 1.6 16.3 72.1 10.1 0 0 8.1 62.5 
**  HercepTestTM conducted at various laboratories compared with FISH at a central facility. 
†  Distribution of sample test scores not representative of population. 
 
The objective of the meta-analysis was to critically assess the literature con-
cerning validity and reliability of IHC and FISH as a basis for a testing strat-
egy, and to provide a cost-effectiveness analysis. Although the inclusion cri-
teria seem to be rather strict, the presented studies differ in many points. 
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Lottner et al. [25] present a new form of HER2 testing by means of FIHC 
(fluorescence IHC, a simultaneous measurement of protein over expression 
and gene-amplification as a multiparameter approach) in 215 primary breast 
carcinoma (node-positive, node-negative, primary tumour or axiliary nodes 
not assessed).The study found 97.7% concordance between conventional IHC 
and FIHC. Cases showing discordance at DNA and protein levels could be 
identified and analyzed in more detail by this simultaneous method. The data 
defined in Table 2 only refer to the conventional IHC and FIHC results.  
Loring et al. [42] compare FISH and CISH in TMA (tissue microarrays) from 
119 archival breast resection cases. The authors conclude that re-testing is 
possible by either FISH or CISH (concordance between FISH (PathVision) 
and CISH (Zymed) was 99%). Intratumoral heterogeneity did not affect a 
patient’s HER2 status (21 IHC 2+ scored cases). 
Dowsett et al. [16] compared local and reference FISH testing in 426 metas-
tatic breast carcinomas (sent in from 37 hospitals and tested in three reference 
centres). The correlation between two analyses (IHC by HercepTest, FISH 
by PathVysion) was calculated. They found very few cases of discordance in 
the 0, 1+ and 3+ samples. The proportion of 2+ varied from seven percent in 
centre 2 to nineteen percent in centre 1. Overall, approximately 50% (30%/ 
40%/82% in the three centres) of the IHC 2+ tumours were found to be 
FISH positive. For a between-laboratory IHC reproducibility study a total of 
60 tumours were re-scored; in all cases the discrepancies were scored 2+.  
This study presents [43] an overview of four different IHC tests (R60 Poly-
clonal Antibody, 10H8 Monoclonal Antibody, HercepTest (Dako) and CB11 
Monoclonal Antibody) and two different FISH (Inform HER2 (Ventana) and 
PathVysion (Vysis). One hundred and seventeen breast cancer specimen were 
previously molecularly characterized for HER2 gene amplification (Southern 
hybridization or slot/blot hybridization – using DNA) and overexpression 
(Northern hybridization or dot/blot hybridization or Western immunoblot – 
assessed by RNA or protein) using solid matrix blotting techniques. Follow-
ing accuracy rates were calculated: FISH: 97.4% for Vysis and 95.7% for 
Ventana. IHC: 96.6% for R60, 95.7% for 10H8, 89.7% for CB11, and 88.9% 
for HercepTest. 
Table 4-2: Sensitivity and specificity of different IHC and FISH tests, taken from Press et al., 2002  
Assay 
No. Positive/ 
No. Negative Sensitivity 95% CI Specifity 95% CI Kappa 95% CI Accuracy 95% CI 
FISH, Vysis 42/75 41/43=0.954 0.842–0.994 73/74=0.986 0.927–1.0 0.945 0.883–1.0 0.974 0.927–0.995
FISH, Ventana 44/73 41/43=0.954 0.842–0.994 71/74=0.960 0.886–0.992 0.909 0.830–0.987 0.957 0.903–0.986
IHC-R60 39/78 39/43=0.907 0.779–0.974 74/74=1.00 0.951–1.0 0.925 0.853–0.997 0.966 0.915–0.991 
IHC-10H8 38/79 38/43=0.884 0.749–0.961 74/74=1.00 0.951–1.0 0.906 0.825–0.986 0.957 0.903–0.986
IHC-CB11 31/86 31/43=0.721 0.563–0.847* 74/74=1.00 0.951–1.0 0.766 0.644–0.888 0.897 0.828–0.946*
IHC-DAKO 30/87 30/43=0.698 0.539–0.828 74/74=1.00 0.951–1.0 0.745 0.618–0.871 0.889 0.817–0.939*
 
Table 4-3: Results on IHC and FISH sensitivity and specificity by Press et al., 2002  
 Sensitivity Specificity 
FISH (pos if HER:CEP 17≥2) 95.4% 98.6% 
IHC (pos if ≥2) 69.8% 100% 
IHC (pos if ≥3) 39.5% 100% 
Lottner et al., 2005: 
97.7% concordance  
IHC & FIHC 
Loring et al., 2005: 
99% concordance 
Dowsett et al., 2003:  
7-19% variances in 2+ 
between laboratories 
Press et al., 200 2: 
accuracy for different 
IHC and FISH tests 
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The authors concluded that the Vysis FISH assay was the most accurate, fol-
lowed by R60, Ventana, 10H8, CB11 and HercepTest. IHC assays had per-
fect specificity, but lower sensitivity. The in-house IHC assays were not sig-
nificantly different from the FISH assays for identification of overexpression 
(although less sensitive). 
Bartlett et al. [44] compared commercial IHC assays and FISH to a more ac-
curate standard Q-IHC (quantitative radio-immunohistochemistry) on 191 
frozen and formalin fixed breast carcinoma sections. HER2 was assessed ret-
rospectively by IHC with HercepTest (Dako), by monoclonal antibody CB11 
(Ventana) and by FISH (PathVision). The accuracy for CB11 IHC was lower 
than for Herceptest or FISH; FISH predicted HER2 overexpression better 
than CB11 IHC or HercepTest. Technical differences among the tests arise 
from strategies to circumvent the effects of tissue fixation and processing. 
Fixation covalently links proteins and nucleic acids, which preserves mor-
phology but “masks” epitopes and decreases tissue permeability to antibod-
ies and DNA probes. IHC-based tests were more susceptible to inter-observer 
variation than FISH. 
Table 4-4: Results on IHC and FISH sensitivity and specificity  
by Bartlett et al., 2001 in Dendukuri 
 Sensitivity Specificity 
FISH (pos if HER: CEP 17≥2) 84.1% 94.6% 
IHC (pos if ≥2) 61.9% 98.6% 
 
A study by Hoang et al. [45] analyzed the concordance between FISH and 
IHC (two different tests) in 100 consecutive cases resulting??? in 91% for Her-
cepTest and 76% for e2-4oo1 monoclonal antibody test. Four pathologists 
completely agreed to IHC scoring (e2-4001 and HercepTest) in 75 and 85 
cases, respectively. 
Kakar et al. [26] presented the results of a comparison of IHC and FISH in 
112 consecutive unselected patients. The concordance was 88% overall (88%/ 
98 of 112 cases among cases with 3+, 35%/6 of 17 cases among the 2+ cases 
and 99%/78 of 79 cases among cases with 0 and 1+ staining). Survival data 
of 65 patients (stratified into 2 groups: survival >50 months and <50 months) 
revealed that patients with IHC results 3+ and FISH signal ratio >4.0, had 
shorter survival rates. However, the numbers in the groups were too small 
for exact interpretations. Costs and turnaround time were greater for FISH.  
Mrozkowiak et al. [46] tested 360 invasive breast cancer specimen, compar-
ing HercepTest and FISH with Oncor-QBiogene. The number of IHC 2+ 
scored samples was much higher compared with other studies presented in 
the meta-analysis. FISH results were divided into three categories: no/low/ 
high amplification. The results are not representative for comparison with 
other studies from the meta-analysis because different methods were used. 
For the 2913 breast cancer specimen in the study of Yaziji et al. [18], both 
FISH and IHC results were available. The concordance rate was 64.9% when 
scores of 2+ and 3+ positive tumour sections were grouped together. The 
sensitivity of IHC, including tumour sections with scores of 2+ and 3+, was 
92.6% and the specifity of IHC tests with scores of 3+ was 98.8%. 
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Lat el al researched the effect of dual-color (D-FISH) versus single-color 
FISH (S-FISH) scoring in 2279 cases of invasive breast carcinoma [32]. The 
study considered a ratio for HER2/chromosome 17≥2 (D-FISH) or an abso-
lute HER2 copy number per nucleus ≥4 (S-FISH) as positive gene amplifi-
cation. Overall concordance in HER2 status with IHC was 87% for D-FISH 
and 86% for S-FISH. The researchers found concordance among groups scored 
by IHC as 0, 1+ and 3+, but not so good in the group scored 2+. Here only 
about a quarter was FISH positive. D-FISH and S-FISH scoring results were 
discordant in 4% (89 tumours), of which 9% (8) had 3+ IHC staining and 
none showed high-level HER2 amplification. 
Table 4-5: Correlation D-FISH/S-FISH, Lal et al., 2000 
 D-FISH 
S-FISH positive negative 
Positive 294 57 
Negative 32 1896 
 
The discrepancy was apparently due to polysomy 17 in tumours that were 
negative by D-FISH and positive by S-FISH and monosomy 17 with concur-
rent duplication of the HER2 gene on the remaining chromosome 17 in tu-
mours that were positive by D-FISH and negative by S-FISH. Among all 
FISH positive tumours, 10% were negative by IHC and almost half (47%) 
showed borderline to low HER2 amplification. This might explain instances 
where there was no response to therapy.  
Even among the FISH-positive tumours scored immunohistochemically as 
2+, the degree of HER2 amplification was significantly lower than that of 3+ 
tumours, but rather similar to that of FISH-positive tumours scored immu-
nohistochemically as negative for HER2. The authors suggest that a relatively 
low level of HER2 amplification observed in the 2+ tumours also might con-
tribute to the lower response rate to Trastuzumab-based therapy = gene dos-
age phenomen. The present study, however, does not permit a determination 
of which FISH assay is better for clinical testing. 
Table 4-6: HER2 amplification of 2+, Lal et al., 2004 
Ratio <2.0 Ratio ≥2.0 Immunohisto-
chemical Score 
Total No. (%) 
of Cases No. (%) Mean (Range) No. (%) Mean (Range) Media 
0 1,017 (44.6) 1,006 (98.9) 1.1 (1–1.9) 11 (1.1) 3.4 (2.0–6.8) 2.4 
1+ 715 (31.4) 693 (96.9) 1.2 (1–1.9) 22 (3.1) 3.5 (2.0–5.9) 2.9 
2+ 313 (13.7) 230 (73.5) 1.2 (1–1.9) 83 (26.5) 3.6 (2.0–10.5) 2.8 
3+ 234 (10.3) 24 (10.3) 1.2 (1–1.7) 210 (89.7) 5.1† (2.1–18.6) 4.7 
Total 2,279 (100.0) 1,953 (85.7) –– 326 (14.3) –– –– 
 
Ogura et al. [47] analyzed 110 specimen of 113 consecutive patients (age: range 
from 27 to 82 years; 42 pre-, 68 postmenopausal) with invasive ductal carci-
noma (IHC performed by HercepTest, FISH by PathVision). They conclude 
that an IHC score of 3+ is FISH positive, while an IHC score of 2+ is not 
equivalent to FISH positive because 90% of the samples analyzed having an 
IHC score of 2+ had discordant FISH results.  
Lal et al., 2004: 
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IHC 2+/25% 
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borderline tumours 
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Table 4-7: IHC/FISH sensitivity taken from Ogura et al., 2004 
 IHC 
 0 + ++ +++ 
FISH  
Neg 26 51 9 0 
Pos 1 2 1 20 
FISH pos rate 4% 4% 10% 100% 
 
Tsuda et al. [48] conducted a study of two independent observers performing 
FISH testing (by PathVision). The study found a good reliability in intratu-
mor heterogenity (there was a concordance of 100% between the invasive and 
intraductal components in all 14 carcinomas). HER2 amplification detected 
by FISH was found to be compatible with the Southern Blot analysis, Her-
cepTest and the own polyclonal antibody Test (Nichirei). The concordance 
was 91% for 2+/3+ IHC results and FISH, with a sensitivity of 70% and 
specifity of 97%. 
McCormick et al. [12] analyzed 215 samples from different hospitals by IHC 
(HercepTest) and FISH (PathVision). The HER2 status concordance was high 
for IHC 0, 1+ and 3+ tumours but poor for 2+ tumours. Two pathologists 
independently scored slides as 0, 1+, 2+ or 3+. Cytoplasmic staining was 
ignored; only invasive tumour was scored. Pathologist concordance was 78% 
overall and 95%, 62%, 75% and 83% for the 3+, 2+, 1+ and 0 IHC group, 
respectively. FISH slides were scored by one observer. When samples were 
grouped as IHC positive (2+, 3+) or IHC negative (0, 1+) the concordance 
was 92% and 96%, respectively. One postulated advantage of IHC analysis 
over FISH for HER2 determination is the potential to detect protein overex-
pression in HER2-nonamplified tumours.  
The authors mention that such overexpression-positive/amplification-negati-
ve tumours occur in 3% to 8% of breast cancers in most series but were as high 
as 29% and 31% in comparison of FISH (PathVision) with IHC (HercepTest) 
and the Genentech CTA, respectively. 
In a study performed by Roche et al. [49], tumour specimens from the first 119 
patients enrolled in the Breast Intergroup Trial N9831 were centrally tested 
(IHC with HercepTest, FISH with PathVision). HER2 status at enrolment 
was determined in one of 65 local laboratories (IHC: 50% by HercepTest and 
42% by other methods, and FISH: 7% by PathVision and 1% by Ventana). 
The study found poor concordance (74%) between local and central testing 
for HER2 status.  
In another study [50], 2600 women were prospectively evaluated by FISH for 
entry in clinical trials. The study found that 26% of the participants had 
HER2 gene amplification. Overall, the HER2 alteration status determined 
by local IHC showed 79% agreement rate with central performed FISH. The 
agreement rate of central and local performed IHC was 77.5%, and for central 
and local performed FISH 92%. Concerning inter-/intralaboratory reproduci-
bility, better agreement between outside and central tests was found for FISH 
as compared to HercepTest. 
In the study of Dolan et al. [51] IHC (by HercepTest) data were available for 
129 specimens. The study found a discordance between IHC and FISH of ap- 
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McCormick et al., 2005 : 
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proximately 92% at IHC scores of 2+ when the data was tested with FISH 
(PathVision). With regard to specimen type (core biopsy cases and excision/ 
excisional biopsy cases: 79% and 62%, respectively) and tumour grade (the 
rates of discordance decreased with increasing tumour grade), a slightly vary-
ing concordance at FISH was found, the tumour type having no statistically 
significant affect on concordance rates.  
 
 
4.2 Conclusions from Meta-Analysis 
The meta-analysis was carried out to estimate the distribution of IHC scores 
and to determine IHC validity (FISH was considered the gold standard). 
Table 4-1 summarizes the results from studies evaluating the concordance be-
tween IHC and FISH. 
Table 4-8: Results of Meta-Analysis (%) 
IHC 0 36.1% FISH: 1.7% pos 
IHC + 35.5% FISH: 3.4% pos 
IHC ++ 12.2% FISH: 29.9% pos 
IHC +++ 16.2% FISH: 91.9% pos 
 
Some trials use different tissues (eg TMA) for testing, showing new options 
for clinical practice, and demonstrate new methods that differ from conven-
tional IHC/FISH ([25]). In two studies ([44] and [43]), authors compared 
IHC and FISH with a third reference standard, the Q-IHC (quantitative ra-
dio-immunohistochemistry) and solid matrix blotting. The lattermethods are 
considered to be more accurate but impossible to use in a clinical setting. 
The researchers found that FISH had a higher sensitivity than IHC and that 
three other IHC assays using different antibodies (R 60 Polyclonal antibody, 
10H8 Monoclonal Antibody, CB11 Monoclonal Antibody) had better overall 
accuracy than HercepTest.  
The currently pursued strategy of confirmatory testing for IHC 2+ cases alone 
is expected to correctly diagnose 96.9% women. 
In general, study results of reliability between/within observers/laboratories, 
demonstrated that the reliability of FISH was better than for IHC [16]. The 
relatively subjective nature of the interpretation of the IHC data may mean 
that less experienced centres are less likely to reach the same level of con-
cordance described in some studies. 
The strategy of performing FISH on all cases is supposed to comprise the 
highest incremental cost-effectiveness ratio (ICER), the strategy of confirma-
tory testing for IHC 2+ and 3+ cases the lowest. 
Overall, the McGill University Health Centre meta-analysis [41] presents re-
sults of HER2 testing gained by different methods in local or central de-
partments. Based on the interpretation of all the results, the authors recom-
mend the confirmation of the positive HER2 status of IHC 2+ and 3+ scored 
specimen by FISH, and an IHC test for patients with a positive FISH test 
alone, performed in a local laboratory. 
Dolan et al., 2005: 
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with increase of tumour 
grade 
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non-approved IHC-tests 
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5 HER 2 Testing: Key Issues 
The majority of published reports examining the impact of HER2 status on 
clinical outcome and response to therapy employed retrospective HER2 test-
ing, primarily by IHC. A major problem when interpreting published stud-
ies of HER2 in the clinical setting is that different methods have been used 
to evaluate HER2 alterations. These methodological differences likely con-
tribute substantially to conflicting results and, therefore, conflicting conclu-
sions [43]. Further, nearly all studies discussed – besides the results achieved 
by different methods used for HER2 testing – also the morphological pat-
terns, and tried to show future possibilities in enhancement.  
Mann et al. [52] discussed the results of 100 consecutive patients, having had 
both core and surgical specimen (no therapy in between). Two pathologists 
examined each slide independently. To assess whether there was a system-
atic tendency for core biopsies to show a positive result more often than the 
corresponding surgical tissue sample, the authors used a log-linear model to 
test the symmetry of the comparison. They noted an occasional disparity be-
tween assay results on core biopsy and surgical specimens.  
Gong et al. [9] discussed different methods of tissue acquisition yield sam-
ples with different cellular compositions. Fine needle aspiration (FNA) sam-
ples mainly contain neoplastic cells and a few infiltrating leucocytes; whereas 
tissue samples contain variable amounts of neoplastic cells, connective tis-
sue, and benign breast epithelium. In this study mRNA-based oestrogen re-
ceptor and HER2 determinations had similar results on both types of sam-
ples. Three of 43 tumours with an IHC score of 3+ were not amplified by 
FISH (PathVysion) with a discordant rate of seven percent.  
These discrepancies are expected because DNA, mRNA and protein degrade 
at different rates and pre-analytical factors (ie, fixation length) affect results. 
When analyzing the results, it is important to be aware that the handling 
and processing of tissue samples before the HER2 assay can affect the results 
(type of specimen, time from excision to fixation, specimen slicing before 
fixation). Therefore, researchers need to standardize the steps and procedures 
involved [53] . 
The fixation time should be between 6 and 48 hours [10]. The staining of the 
tissue – elapsed time between fixation and staining is important. Prolonged 
storage of unstained slides can result in significant loss of immunostaining 
intensity for some antigens/antibodies [20]. HercepTest relies on samples be-
ing fixed by a defined protocol (kit insert). Fixation preserves morphology but 
decreases tissue permeability to antibodies and DNA probes [44]. Overfixa-
tion can produce negative results because formalin suppresses the antigenic-
ity [54]. Formalin fixation for four days or longer might produce inaccurate 
data by FISH, and formalin fixation for one week or longer might result in 
inaccurate IHC results.  
The circumstances that take place prior to analysis, such as the time between 
removal of the tissue (tissue acquisition) by fine-needle aspiration, core bi-
opsy, surgical resection and embedding in formalin (fixation), are important 
to the results.  
This time period should be minimized to be as short as possible. That could 
be a problem in hospitals, where surgery departments are not in physical 
proximity to pathological laboratories. 
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The antibodies are developed from animals immunized with native, nonfixed 
HER2 protein as antigen. In some formalin-fixed breast cancer specimens 
HER2 is not recognized because none of the HER2 antibodies were produced 
using formalin-fixed HER2 protein as antigen [43].  
The IHC test is not performed consistently across laboratories and every coun-
try has its own f’avoured methods. By comparing studies in which the au-
thors comment on the interpreting and scoring of IHC-stained slides, the per-
centage of positively staining cells, the intensity and location (cytoplasmic 
versus membraneous, and ductal carcinoma in situ versus invasive compo-
nent) of staining, and the positivity cut-off used is to be considered [20]. Few 
of the laboratories have validated their immunohistochemical staining assess-
ments using standardized specimens with known molecular changes. A large 
number of pathology laboratories use in-house reagents and protocols with 
widely varying sensitivity, specifity, reproducibility and practicability [20]. 
The identification of patients with high HER2 expression by Q-IHC is un-
suitable for routine diagnostics. Many studies refer to accuracy of the Her-
cepTest. Vincent-Salomon et al. [55] used different IHC tests for HER2 at a 
multicenter level, and achieved accuracy of 93% and 95% for the HercepTest.  
One study [56] investigated the effect of chromosome 17 copy number in de-
termining HER2 status in breast cancer .When a ratio ≥ 2 was considered as 
criterion for FISH positivity, 49.3% of cases showed amplification, 56.2% by 
using a net HER2 gene copy number >4 as an alternative criterion. A net 
increase in HER2 gene copy number consecutive to polysomy 17 in the ab-
sence of specific gene amplification might lead to a strong protein overex-
pression in a small subset of breast carcinomas. 
Polysomy 17 is responsible for discordance in HER2 status as defined by dif-
ferent FISH scoring systems [15]. Best concordance was found with the HER2/ 
CEP17 ratio and HER2>6 scoring. An alternative for the clinical practice 
could be the correction for chromosome17: HER2 >6, but not HER2 >4 as 
alternative. Varsheney et al. [57] found the incidence of chromosome 17 poly-
somy in 2+ non-amplified cases to be similar to the incidence of polysomy 
of 17 in negative cases. The findings indicate that weak overexpression (2+) 
of HER2 without gene amplification is not secondary to chromosome 17 poly-
somy.  
A parallel trend was observed between progressively higher levels of FISH 
signals and ascending IHC staining categories [58]. Both FISH (corrected or 
uncorrected for chromosome 17 polysomy) and IHC findings were found to 
be independent predictors of poor survival in multivariate analysis. 
Researchers have established the 2+ category of IHC as the main source of 
discrepancy between IHC and FISH results [32]. The variability in definition 
and use of a borderline interpretation may be partly the result of different 
interpretations of the FISH-PathVision kit insert (ratio of 1.9 should be re-
ported as no amplification, of 2.1 as amplification, and near the cutoff of 
1.8–2.2 should be interpreted with caution).  
Aneusomy (additions or deletions of entire chromosomes) seems to be re-
lated to a particular subset of 3+ cases whose biology should be further in-
vestigated [59]. Cases with 2+ and 3+ scores are associated with a weakly/ 
moderately and intensely positive membrane in more than ten percent of to-
tal tumour cells. Among all FISH positive tumours, 10% were negative by 
IHC; almost half (47%) showed borderline to low HER2 amplification. This 
could explain instances where there was no response to therapy [32]. Lewis 
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et al. [60] used tumor-bearing blocks from 20 invasive breast carcinomas with 
IHC scores of 2+ with gene amplification and from eighteen cases with IHC 
scores of 2+ without gene amplification.  
They found a significant degree of intratumoural heterogeneity with respect 
to HER2 protein expression. Overall, 68% of the 2+ cases would have had a 
different immunohistochemical score if another slide(s) had been examined. 
They observed that staining heterogeneity, within a slide and in different 
blocks of a tumour, is a feature of 2+ staining tumours. 
Many studies found poor correlation between weak positive IHC scored speci-
men and the evaluated FISH results (ie, [61]). Killeen et al. [62] compared 
IHC and FISH results with tumour morphology and found that borderline 
HER2 tumours are a unique tumour type and do not represent laboratory 
imprecision. Whether borderline amplification is correlated with sensitivity 
to therapy is unknown [54]. 
Table 5-1: Tumor characteristics and HER-2 status 
Killeen et al., 2006, page 101 
 HER-2 neg HER-2 borderline HER-2 pos p Difference 
Age, mean 60.40 61.30 56.86 0.029 Pos < Neg or Bord 
Tumor grade (mean score) 1.75 1.89 2.57 <0.001 Pos > Neg or Bord 
Nuclear mean score 1.91 2.04 2.54 <0.001 Pos > Neg or Bord 
Tubule mean score 2.38 2.57 2.83 <0.001 Pos > Neg or Bord 
Mitotic mean score 1.47 1.55 2.20 <0.001 Pos > Neg or Bord 
Ki-67 mean % 15.73 15.60 21.23 NS  
ER, % positive cases 86.00 84.00 42.00 <0.001 Pos < Neg or Bord 
PR, % positive cases 72.00 61.00 28.00 <0.001 Pos < Neg or Bord 
HER-2 copy # (mean) 2.24 4.10 13.57 <0.001 Pos > Neg > Bord 
 
For tumours with low-level or equivocal amplification, future surveys will 
have to face additional challenges to more accurately define interlaboratory 
variability in HER2 FISH analysis near the critical cut-off range. Breast tu-
mours with low and with high copy numbers at HER2-amplification have 
excellent reproducibility. However, there still needs to be a consensus on the 
use of a separate equivocal/borderline interpretative category for standardi-
zation of cutoff values used to define interpretative categories. McCormick 
et al. [12] found a high concordance between two pathologists (only invasive 
tumour tissue was scored). The authors of another study reported high agree-
ment levels for tumours with IHC scores of 0, 1+ and 3+, but poor for tu-
mours with IHC score of 2+ by 6 specialized pathologists [54]. 
Many studies present the problem of unsatisfying concordance IHC/FISH 
and IHC/IHC (from different manufacturers). One study [33] showed HER2 
overexpression determined by IHC (HercepTest) in 19%. FISH (PathVysion) 
performed on equivocal cases demonstrated HER2 amplification in 18%. 
IHC and FISH together showed HER2 overexpression/gene amplification in 
21% of breast invasive carcinoma. Another study [28] compared IHC using 
CBE356 with the HercepTest in formalin fixed, paraffin wax embedded 
blocks of 167 carcinoma, previously analyzed by FISH (PathVision). Overall 
CBE 356 antibody was a more accurate predictor of HER2 gene amplifica-
tion by FISH than the HercepTest.  
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Table 5-2: Comparison of two IHC Tests (2+, 3+ positive cases)  
Ainsworth et al., 2005 [28] 
 Accuracy Sensitivity Specifity PPV NPV 
CBE56 94% 89% 95% 84% 97% 
HercepTest 91% 66% 98% 92% 91% 
 
In another study of Dybdal et al. [63] the overall concordance between FISH 
and IHC results was 82% (in 529 fixed breast cancer tissue specimens).  
Birner and al. [64] found a good correlation between FISH (PathVysion) and 
four different IHC tests. The study population consisted of 303 unselected 
cases of invasive breast cancer, 207 cases were analyzed. The authors of an-
other study [59] discussed results of IHC and FISH on 81 archival formalin-
fixed and paraffin embedded specimens. Data described in the literature for 
3+ carcinomas showed a 3%–10% discrepancy between protein expression 
and gene amplification In their study the difference was up to 22%. Reddy et 
al. [65] presented data that show a higher concordance between HER2 IHC 
and FISH when both tests are performed at a central laboratory. Researchers 
analyzed 923 breast cancer patient samples using IHC (HercepTest and a 
test with the R60 antibody) and FISH (one test with total number of cells, 
the other using the ratio) [66]. Sensitivity and specifity of FISH were supe-
rior to IHC. HercepTest showed more false-negative results. 
The authors of one study [48] found a concordant amplification status be-
tween the invasive and intraductal components. Hoff et al. [11] presented 
data from 401 invasive carcinomas. Invasive ductal carcinomas were more 
likely to demonstrate HER2 amplification than invasive lobular carcinomas, 
and among the invasive ductal carcinomas higher grade invasive more than 
lower grade. Researchers suggest re-examination of tumours diagnosed as 
SBRgrade 1 invasive ductal carcinomas or lobular carcinomas. Ductal of no 
special type was the predominant cancer type (81.5%) in a study discussing 
the prediction of HER2 status in 1540 specimen [67], followed by ten per-
cent of infiltrating lobular carcinomas of classical variant. Researchers have 
found a strong correlation between HER2 3+ and infiltrating ductal carci-
noma, grade 2 and 3, suggesting a predominant HER2 positive phenotype. 
Variability in sensitivity exists because formalin-fixation and paraffin-em-
bedding adversely effect antigenicity and immunostaining of the vast major-
ity of protein antigens, and the ability of antibodies to recognize their epi-
tope varies from antibody to antibody [43]. The sensitivity of IHC, including 
tumour sections with scores of 2+ and 3+, was 92.6% and the specifity of IHC 
tests with scores of 3+ was 98.8% [18]. In 101 cases [48], the overall concor-
dance of 93% was found between FISH (PathVision) and DNA amplifica-
tion by Southern Blot: 93%, with a sensitivity of 76% and a specifity of 96%. 
Variation in assay sensitivity was studied in twenty-six laboratories [29]. 
Laboratories using HercepTest had the highest level of reproducibility in as-
say sensitivity and evaluation. The reported sensitivity of the HercepTest 
varied among centres. 
In some studies, two pathologists independently estimate the same specimen. 
The subjective nature of interpreting the intensity of IHC staining repre-
sents a particular inherent weakness of this testing method [20]. Studies ex-
amining the issue of intra-observer variability of HER2 IHC interpretation 
have found a high level of agreement with regard to the presence or absence 
of membrane staining, but a low level of agreement with intensity and extent 
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of tumour membrane staining. Intra-observer reproducibility was generally 
not satisfactory [68]. IHC-based tests are more susceptible to intra-observer 
variation than FISH [44], [24] . Studies found FISH testing by two independ-
ent observers highly reproducible in determinating HER2 DNA amplifica-
tion, independent of intratumour heterogeneity [48] . The concordance was 
99%. Even at stratification in low-level and high-level amplification, concor-
dance was achieved in 98%. 
In the study of McCormick et al. [12], pathologist concordance was 78% over-
all and 95%, 62%, 75% and 83% for the 3+, 2+, 1+ and 0 IHC group, re-
spectively. When samples were grouped as IHC positive (2+, 3+) or IHC 
negative (0, 1+), the concordance was 92% and 96%, respectively; FISH slides 
were scored by one observer. Another study [54] found FISH testing by two 
independent observers to be highly reproducible in determining HER2 DNA 
amplification, independent of intratumour heterogenicity (there was a con-
cordance of 100% between the invasive and intraductal components in all 
fourteen carcinomas) [54]. FISH was found to be correlated with the status 
of the DNA amplification detected by Southern blot hybridization. 
In another study [69] a significant number of laboratories changed their in-
terpretation from one year to the next for the same case with low-level am-
plification, indicating potentially poor reproducibility within individual labo-
ratories. The study examined the results of the eighty-three laboratories that 
submitted interpretation for both 2002 and 2003. 
Table 5-3: Intra-laboratory Interpretation of Repeated Equivocal/Borderline Cases,*  
taken from [69]  
 Amplification 
2003 
No Amplification 
2003 
Equivocal/ 
Borderline 2003
Amplification 2002 44 3 2 
No Amplification 2002 23 6 5 
* Total number of laboratories = 83 
 
An inter-laboratory study [27] discussed the reproducibility of HER2 testing. 
HER2 was evaluated by IHC on archival primary breast cancer samples. Both 
laboratories used the primary antibody NCL-CB 11. The study found that 
HER2 evaluation by IHC was not reproducible when there is no standardi-
sation of the procedure. In an Italian Quality Assurance Initiative [70], twenty 
immunostained slides were distributed to twelve pathologists. Inter- and in-
tra-observer reproducibility was good. The authors concluded that 0ne of the 
reasons why a high percentage of tumours classified as positive for HER2 do 
not respond to anti-HER2 therapy may be in the lowest class for both the 
percentage of immunostained cells and membrane intensity. In the Italian As-
surance Initiative from 2005 [68], the intra-observer reproducibility was gen-
erally satisfactory, but the inter-observer reproducibility was not. Seventeen 
slides were scored by twenty-three observers – the HercepTest did not allow 
to discriminate optimally between scoring classes 2+ and 3+. 
Largely due to inadequate resources, probes sent to different pathological 
laboratories are not estimated by pathologists twice. According to the litera-
ture, eighteen percent [71] and twenty-six percent [49] of patients who en-
tered into clinical trials as HER2 positive on the basis of local testing, were 
negative when their probes were tested centrally. Scientific literature has dis-
cussed the issue of poor concordance between local and central testing [49]. 
poor reproducibility 
within laboratories 
problem of local and 
central laboratories 
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In general, studies of reliability between/within observers/laboratories have con-
cluded that the reliability of FISH is better than of IHC.  
However, currently relatively few diagnostic laboratories have expertise in 
FISH analysis. Therefore, poor agreement often occurs between results from 
local and central laboratories. It seems that although intra-observer repro-
ducibility is generally satisfactory; inter-observer reproducibility is not [68]. 
In regards to inter-/intralaboratory reproducibility, studies have found a bet-
ter agreement between outside and central tests on the FISH than on the 
HercepTest [50]. IHC 2+ category is most likely to be discordant with FISH. 
False-positive and false-negative HER2 results can have different sources of 
error, most likely resulting from methodological problems (i.e., lack of qual-
ity-control procedures in local laboratories). For example, among patients 
found to be strongly HER2 positive by local laboratories, 18.4% from IHC 
(HercepTest) and 11.9% from FISH (PathVysion) were unconfirmed when 
re-tested at a central laboratory [72]. The inter-observer variability is likely 
to be higher than in studies in which consensus IHC scores are obtained be-
fore performing FISH [51]. In the reliability study of Dowsett et al. [16], the 
discrepancies concerned primarily the 2+ category. The proportion – 13% of 
tumours IHC 2+ and overall 48% of these FISH positive – varied markedly 
between the centres. Sixty IHC-stained slides selected to be enriched with 
2+ cases were circulated among the three laboratories and scored (twenty 
cases with discordance in scoring, the consideration with FISH ? concor-
dance in nineteen cases). The proportion of 2+ varied from seven percent in 
centre 2 to nineteen percent in centre 1.  
Overall, approximately fifty percent (30%/40%/82% in the three centres) of 
the IHC 2+ tumors were found to be FISH positive. The relatively subjec-
tive nature of the interpretation of the IHC data may mean that less experi-
enced centres are less likely to reach the same level of concordance.  
Every pathology laboratory involved in IHC testing should validate its IHC 
test and interpretation by comparing IHC test and FISH results on a sizeable 
set of tumours (e.g. 100 cases) and using that set as a guide for IHC scor-
ing [73]. 
In another study [63], the concordance rate between two laboratories was 
92%, indicating that FISH results were reproducible in archived specimens, 
even when they had been previously processed using IHC staining. The re-
sults suggest that FISH would exclude a significant number of women from 
clinical trials in both the IHC 2+ and IHC 3+ categories whose breast can-
cers do not have HER2 gene amplification. The study discussed possible over-
diagnosis of HER2+ status in small-volume laboratories. 
Because strongly positive (3+) cases (IHC) represent only 15–20% of newly 
diagnosed breast cancer cases, pathologists in small-volume laboratories may 
over-anticipate positive cases, leading to interpretation bias. Such bias would 
be likely to occur less in a large-volume setting [74].  
HER2 status at enrolment was determined in one of 65 local laboratories 
(IHC: 50% by HercepTest and 42% by other methods, and FISH: 7% by 
PathVision and 1% by Ventana). A poor concordance (74%) between local and 
central testing for HER2 status was found [49]. 
An inverse relationship exists between oestrogen receptor (ER) positivity and 
HER2 positivity. One study [13] correlated HER2 amplification with lower 
ER and HER2 protein over-expression. The data showed that the ER levels 
few diagnostic 
laboratories have 
expertise in FISH 
less experience means 
less concordance 
potential for  
over-diagnosis 
problem of hormone 
status 
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are one-half to one-third lower in HER2 negative/ER positive cancers than 
in HER2 negative/ER positive tumours. The same study found FISH/IHC 
concordance in 84.6%. Taucher et al. [75] showed in their study (923 con-
secutive patients) that HER2 over-expression is correlated significantly with 
negative estrogen (ER) and progesterone receptor (PR) status, Grade 3 lesions 
and young age. Gene expression data (profiled on Affymetrix U133A Gene 
Chips) of 495 breast cancer samples (FNA samples and tissue samples) were 
used [9] to assess the correlation between mRNA concentrations and the rou-
tinely established clinical receptor status of oestrogen receptor and HER2. 
More than twenty percent of HER2 positive tumours showed moderate or 
strong staining for ER [76]. But the oestrogen status could not be used to se-
lect tumours for evaluation of HER2 status, and ER and PR positivity does 
not preclude a positive HER2 status according to these results. 
Elkin et al. presented a cost-effectiveness analysis [77]. A state-transition 
model was created to simulate clinical practice in a hypothetical cohort of 65-
year-old metastatic breast cancer patients and cost-effectiveness of alterna-
tive HER2 testing was estimated. Compared with IHC, FISH is more expen-
sive, time consuming, and labor-intensive. But FISH has a more objective and 
quantitative scoring system and is also more predictive than IHC of response 
to trastuzumab. The additional costs must be weighed against the savings 
that result from avoiding treatment of women with false positive result. Base-
case analysis suggests that no alternative exists to a policy of IHC with FISH 
conformation of all positive results. 
In spite of quality control, sometimes the FISH assay needs to be repeated. 
This can occur, for example, when two appropriate areas of invasive tumour 
cannot be identified in the tissue section, controls fall outside the expected 
values, hybridization signals are not uniform, background is too high or ob-
scures the signals, or enzymatic digestion is not optimized to produce scorable 
signals. The additional time and the direct laboratory expense involved with 
FISH testing need to be carefully weighed against the cost of inappropriate 
classifications, and thus, inappropriate treatments of patients. The cost of 
treating a patient with trastuzumab vastly exceeds the direct laboratory ex-
penses of a FISH test [78].  
One of the cost-effectiveness analyses indicates that it is more cost-effective 
to use FISH alone or as a confirmation of all positive (scores 2+ and 3+) re-
sults than using FISH to confirm only weakly positive results (2+) or using 
IHC alone [54]. 
Many studies comparing the HER2 status between primary and metastatic 
sites reported concordance rates as 87.6%–100%; the HER2 status of 37.5% 
of patients with HER2 negative primary breast cancer became positive when 
relapse occurred; among distant metastatic foci, there was heterogeneity in 
the HER2 status [54]. For the evaluation of HER2 status in the primary site, 
the invasive component should be determined, and the non-invasive compo-
nent should not be determined because only the invasive component is be-
lieved to metastasize. 
A study conducted by Di Leo et al. found that the evaluation of HER2 status 
on primary tumour appears to reflect the HER2 status of corresponding me-
tastatic sites from the same patient [79]. The authors refer to studies where 
the level of concordance ranged from approximately 80%–100%. In an other 
study [59] Rossi et al. found that there was a good concordance between Her-
cepTest negativity and FISH non-amplification. Eighty percent of 25 cases 
(2+) turned out to be non amplified in FISH and only twenty percent were 
problem of costs 
avoidance of 
inappropriate treatment 
of false positive 
problem of primary/ 
metastatic site 
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amplified. As a consequence of this study the authors recommend that all 
2+ and 3+ IHC scored cases should be tested by FISH.  
Volpi et al. [80] tested the pure prognostic value of HER2 over-expression, 
according to internationally proposed guidelines and failed to find a relevance 
of any cut-off value of HER2 over-expression on RFS/ recurrence-free sur-
vival. 
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6 Summary & Conclusion 
This assessment summarizes results from studies concerning routine use of 
state of the art testing for HER2 status. Determination of HER2 status is now 
an integral part of clinical-pathological exams for breast cancer patients. The 
development of novel methods and new markers has also led to new insights 
in the physiology status of HER2 and has gained increasing significance in 
helping at interpretation of results during the past years. 
Discussions involving published HER2 testing results have to take into con-
sideration the number of included specimen, the art of tissue extraction, his-
tology of the specimen, and methods used (particularly studies involving large 
multi-local trials may utilize different methods). Data should include exact 
information on which tests were used because of small variations in commer-
cial tests and the influence of different (even approved) tests on the interpre-
tation of results. 
IHC results show much greater variability than FISH – test results, particu-
larly for the FISH negative cases [81]. The results of most presented studies 
indicate that high-level HER2 amplification and an IHC score of 3+ well 
identify breast carcinoma; the low-level amplification and/or IHC score of 
2+ should be carefully interpreted.  
Furthermore, an uncertainty exists on the clinical significance of low level 
gene amplification concerning response to trastuzumab. In addition, the tar-
get for trastuzumab is the protein and the gene is only the surrogate marker 
of the true target [82]. There are patients who respond to trastuzumab, if the 
tumour is positive for HER2 by IHC, irrespective of whether or not gene am-
plification is present. Using current methods, the ability of positive predic-
tive values (PPV) of the receptor status to predict benefits from trastuzumab 
treatment is modest (25%–40%) [9]. There might be alternative methods of 
protein over-expression to gene amplification.  
IHC errors in interpretation potentially could represent an overestimate of 
“minimal” (0, 1+) staining or an underestimate of “strong” (3+) staining. A 
dual probe FISH assay should be used because of its ability to distinguish 
HER2 gene amplification from chromosome 17 polysomy. As breast cancer 
research continues to identify additional factors associated with HER2 am-
plification, data models try to include those factors but provide only guide-
lines to clinical expectations. New findings on the molecular or genetic level 
can influence the interpretation of results. Results from large trials are in-
teresting for clinical practice: a multivariable analysis [83] of prospectively 
collected data (1083 patients – 872 HER2 non-amplified, 211 HER2 ampli-
fied) showed that correlates of HER2 amplification are higher SBR grade, 
younger age at diagnosis and a comedo ductal carcinoma in situ component. 
 
Many problems and uncertainties still exist. Only a few studies refer to mod-
erate inter-observer reliability. Discussing the testing results of one probe 
tested in the same location but at different times is rarely possible. The find-
ings concerning different results from local/central laboratories are important.  
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A high number of probes in a reference or central laboratory seems to be an 
advantage. Quality assurance at small-volume laboratories (those processing 
fewer than approximately one hundred HER2 tests a month) appears to be a 
problem due to less practice in processing methods. Furthermore, the algo-
rithms of testing differ in various countries: the results often do not repre-
sent the same relevant outcome because of a different procedure implementa-
tion.  
A problem is the difference in the interpretation of probes. Tests should be 
performed according to strict guidelines. Quality control is very important 
when performing HER2 tests, both internal and external, for routine diagno-
sis and in clinical protocol studies [54]. All clinical laboratories using assays 
for HER2 diagnostics (as predictive or prognostic tests) should participate in 
an appropriate external quality assurance (EQA) program.  
Standards based on criteria that has been clinically validated have to be set 
for assay performance and interpretation of assay results. In spite of prevalent 
agreement between HER2 results obtained by IHC and FISH, there are cases 
in which results are discordant, particularly among tumours with intermedi-
ate results. One way to make results more accurate is to implement higher 
standards and the attachment to interlaboratory comparisons, for example, 
organized by Networks for quality assessment of tumour biomarkers [68]. The 
implementation of more accurate tests can influence the analogy of the re-
sults of other studies. 
Cost-effectiveness is also important. How necessary and essential is more ac-
curate testing from the very beginning? Authors from various studies seem to 
concur that the most cost-effective strategy is to screen all patients with IHC, 
and follow up with confirmatory FISH testing in those patients with an IHC 
of 2+ (or of 2+ and 3+). As pathological departments make more of their 
results available on national and international levels, their results will gain 
greater acceptance. All laboratories performing HER2 testing for clinical pur-
poses should use methods that have been proven to have results with high 
levels of concordance with another validated test. 
Based on the results of this assessment, there seem to be less HER2 positive 
women than generally reported in clinical treatment studies: not 20-30%, but 
rather 15-20% are amplifying HER2 positive in “real life” settings. From a 
societal perspective, the diagnostic performance of the test used to identify 
trastuzumab candidates has considerable influence on cost-effectiveness – in-
dependent of test cost – due to the high cost of treating patients with false-
positive test results and the inability of patients with false-negative results to 
benefit from trastuzumab [77]. Increased efforts in accurate testing results 
might lead to less trastuzumab treatments associated with clinical important 
adverse events: less might be more. True evidence-based clinical validation of 
the prognostic and predictive utilities of biomarker tests is performed only 
through prospective clinical studies in which rigorous quality control meas-
ures are systematically implemented and reported [84]. Although more than 
23,000 patients (specimen) have been reviewed in the seventy-five studies pub-
lished in recent years, many unsolved questions remain. 
 
volume/experience of 
laboratories: 
high volume >100 HER2 
probes, advantage;  
low volume <100 HER2 
probes, potentially 
problematic 
 
standardization; 
adherence to strict 
instructions 
 
external QA 
 
performance evaluation:  
rules for handling 
disconcordant results 
and validation with 
clinical results 
cost-effective testing 
strategy:  
 
all patients with IHC, 
followed by FISH for 
IHC of 2+  
(or of 2+ and 3+) 
identification of 
patients that benefit 
from trastuzumab 
should be prioritized for 
clinical and cost reasons 
 
 
many unsolved 
questions 
 LBI-HTA | 2007 41 
7 Excursus: Interpretation for Austria 
About 4,000 breast carcinomas are newly diagnosed in Austria each year. HER2 
status testing is performed as part of a routine clinical exam for any patient 
newly diagnosed with invasive breast cancer. 
Immunohistochemical determination of HER2 status represents an easy and 
standardized method that can be performed in any of the thirty-six pathol-
ogy laboratories that have an IHC department. The mostly used test in Aus-
tria is the HercepTest by DAKO. Standardization of fixation protocols, auto-
mation of the immunohistochemical procedure, and pathologist training in 
scoring need to be priorities in assuring the reliability of results. 
Attendance at national inter-laboratory tests for IHC is organized. 
Cases with equivocal IHC results are analysed by FISH (that can be per-
formed in 22 pathology departments). The most commonly used test is Path-
Vision by Vysis, distributed by Abbott.  
Table 7-1: FISH diagnostic in Austria (Jan 2007)  
Vienna General Hospital, Hietzing Hospital, SMZO Hospital, 
KFJ, Hanusch, Baumgartner Ho¨he, Rudolfstiftung 
Lower Austria Mistelbach, Wiener Neustadt, Horn 
Upper Austria Linz General Hospital, Linz Barmherzige Schwestern, 
Wels Kreuzschwestern, Vo¨cklabruck 
Salzburg State Hospital 
Tirol State Hospital (only surgery, Gyn a` Graz) 
Vorarlberg State Hospital Feldkirch  
Carinthia State Hospital Klagenfurt, State Hospital Villach 
Styria Graz State Hospital, State Hospital West 
Burgenland Oberwart 
 
National and international inter-laboratory tests for FISH do exist, but atten-
dance is optional. 
Comparative studies have shown high concordance rates between IHC analy-
ses and FISH in cases with IHC scores of 0 or 1+ (negative) and 3+ (strongly 
positive) and low concordance rates among cases with IHC scores of 2+. Since 
the meta-analysis [41] and further studies discussed in this assessment in-
clude a great variety of different HER2 testing methods, different problems 
concerning quality, validity, etc. have become apparent.  
In Austria for IHC the HercepTest by DAKO is used most often, for FISH 
the PathVision by Vysis, both approved by FDA. Studies included in this re-
view include results of more than 23,000 specimens of patients. Only a part 
of these specimens were available for both IHC and FISH performed by 
FDA-approved tests, and among them only partially by HercepTest and by 
PathVision. The presented results allow an interpretation for/comparison 
with Austrian data because of the implementation of the same tests in most 
pathology departments. 
HER2 testing  
part of routine 
IHC testing in  
36 laboratories 
FISH testing in 22 
pathologies: highly 
decentralised 
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Table 7-2: IHC/FISH sensitivity  
([18], [16], [32], [50], [49], [51], [12], [28], [64], [85], [47]) 
 FISH 
 Pos neg 
IHC 3+ 1028 142 
IHC 0.1+ 124 4409 
 
The results of eleven studies ([18], [16], [32], [50], [49], [51], [12], [28], [64], 
[85], [47]), in which only IHC by HercepTest and FISH by PathVision were used, 
do not include IHC 2+ scored results because of diversified interpretations 
of the diagnosis of borderline findings and the general acceptance of ambi-
guity of the findings. Of the patients with 0.1+ results (IHC) 2.7% (124) were 
false negative, if retested with FISH, of the patients with 3+ results 12.1% 
(142) were false positive.  
 
sensitivity of IHC/ 
FISH diagnostic:  
2.7% false negative, 
12.1% false positive 
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8 Recommendations 
One has to stay aware, even if FISH is the more reliable and reproducible test 
compared to IHC, nevertheless the therapeutic antibody trastuzumab targets 
the protein. Amplification is merely a surrogate for protein-expression. HER2 
diagnostic is broadly used and decisive for the clinical management of HER2 
positive breast cancer, but it is still a field “under way”. Internationally the 
“state of the art” is to screen all patients with IHC, and follow up with con-
firmatory FISH testing in those patients with an IHC of 2+ (or of 2+ and 
3+). 
The following recommendations are extrapolated from the results of this re-
view:  
b Due to the high variability between the different IHC-tests, we recom-
mend using only standardized and approved tests. 
b Due to the consequential costs (non-monetary costs/side effects of therapy 
and monetary costs), we recommend to establish SOPs/standard operating 
procedures. 
b Due to high inter-laboratory variabilties, we recommend using a small 
number of reference centers rather than decentralised testing locations 
with lack of routine. 
b Due to high inter-laboratory variabilties, we recommend national and in-
ternational inter-laboratory exchange on results of diagnostic outcome. 
 
 
standardization, 
performance control, 
reference centers 
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Appendix  
Search in Databases 
Search strategy for Cochrane CENTRAL 
Date: 2007-01-25 
Database: EBM Reviews – Cochrane Central Register of Controlled Trials 
<4th Quarter 2006> 
Provider: Ovid 
 1 exp breast neoplasms/  
 2 (breast adj4 (cancer$ or carcinoma$ or tum?r$ or malignant$ or  
oncolog$)).ti,ab.  
 3 or/1-2  
 4 immunohistochemistry/  
 5 IHC.ti,ab.  
 6 immunohistochemi$.ti,ab.  
 7  in situ hybridization, fluorescence/  
 8 FISH.ti,ab.  
 9 or/4-8  
 10 receptor, erbB-2/  
 11 Her2.ti,ab.  
 12 HER2.ti,ab.  
 13 or/10-12  
 14 (assay adj method$).ti,ab.  
 15 algorithms/  
 16 “quality assurance (health care)”/  
 17 quality control/  
 18 (quality adj control).ti,ab.  
 19 reproducibility of results/  
 20 validity.ti,ab.  
 21 gene amplification/  
 22 concordan$.ti,ab.  
 23 correspond$.ti,ab.  
 24 discordan$.ti,ab.  
 25 or/14-24  
 26 9 and 13  
 27 3 and 26  
 28 25 and 27  
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Search strategy for Medline  
Date: 2007-01-26 
Database: Medline 1950 to Present with Daily Update 
Provider: Ovid 
 1 exp breast neoplasms/  
 2 (breast adj4 (cancer$ or carcinoma$ or tum?r$ or malignant$ or  
oncolog$)).ti,ab.  
 3 or/1-2  
 4 immunohistochemistry/  
 5 IHC.ti,ab.  
 6 immunohistochemi$.ti,ab.  
 7 in situ hybridization, fluorescence/  
 8 FISH.ti,ab.  
 9 or/4-8  
10 receptor, erbB-2/  
11 Her2.ti,ab.  
12 HER2.ti,ab.  
13 or/10-12  
14 “sensitivity and specificity”/  
15 sensitivity.ti,ab. 
16 specificity.ti,ab.  
17 (assess$ adj5 status).ti,ab.  
18 (determin$ adj5 overexpression).ti,ab.  
19 (determin$ adj5 status).ti,ab.  
20 (detect$ adj5 status).ti,ab.  
21 (detect$ adj5 amplification).ti,ab.  
22 (evaluation adj5 status).ti,ab.  
23 (evaluation adj5 method$).ti,ab.  
24 (assay adj method$).ti,ab.  
25 algorithms/  
26 exp diagnostic errors/  
27 “quality assurance (health care)”/  
28 quality control/  
29 (quality adj control).ti,ab.  
30 reproducibility of results/  
31 validity.ti,ab.  
32 concordan$.ti,ab.  
33 discordan$.ti,ab.  
34 correspond$.ti,ab.  
35 or/14-34  
36 9 and 13  
37 3 and 36  
38 35 and 37  
39 (letter or editorial or case reports).pt.  
40 38 not 39  
41 *prostatic neoplasms/  
42 *urinary bladder neoplasms/  
43 *stomach neoplasms/  
44 or/41-43  
45 40 not 44  
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Search strategy for Embase 
Date: 2007-01-26 
Database: EMBASE <1988 to 2007 Week 03> 
Provider: Ovid 
 1 exp breast tumor/  
 2 (breast adj4 (cancer$ or carcinoma$ or tum?r$ or malignant$ or  
oncolog$ or neoplasm$)).ti,ab.  
 3 or/1-2  
 4 immunohistochemistry/  
 5 IHC.ti,ab.  
 6 immunohistochemi$.ti,ab.  
 7 fluorescence in situ hybridization/  
 8 FISH.ti,ab.  
 9 or/4-8  
 10 epidermal growth factor receptor 2/  
 11 Her2.ti,ab.  
 12 HER2.ti,ab.  
 13 or/10-12  
 14 “sensitivity and specificity”/  
 15 sensitivity.ti,ab.  
 16 specificity.ti,ab.  
 17 (assess$ adj5 status).ti,ab.  
 18 (determin$ adj5 overexpression).ti,ab.  
 19 (determin$ adj5 status).ti,ab.  
 20 (detect$ adj5 status).ti,ab.  
 21 (detect$ adj5 amplification).ti,ab.  
 22 (evaluation adj5 status).ti,ab.  
 23 (evaluation adj5 method$).ti,ab.  
 24 (assay adj method$).ti,ab.  
 25 algorithm/  
 26 exp diagnostic error/  
 27 diagnostic accuracy/  
 28 (quality adj control).ti,ab.  
 29 reproducibility/  
 30 reliability/  
 31 validity.ti,ab.  
 32 concordan$.ti,ab.  
 33 discordan$.ti,ab.  
 34 intermethod comparison/  
 35 or/14-34  
 36 9 and 13  
 37 3 and 36  
 38 35 and 37  
 39 (conference paper or editorial or letter or proceeding).pt.  
 40 38 not 39  
 41 *prostate carcinoma/  
 42 *bladder carcinoma/  
 43 *stomach carcinoma/  
 44 or/41-43  
 45 40 not 44 
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Search strategy for Biosis Previews 
Date: 2007-01-26 
Database: BIOSIS Previews <1990 to 2006> 
Provider: Ovid 
 1 breast neoplasms.ds.  
 2 (breast adj4 (cancer$ or carcinoma$ or tum?r$ or malignant$ or  
oncolog$)).ti,ab.  
 3 or/1-2  
 4 IHC.ti,ab.  
 5 immunohistochemi$.ti,ab.  
 6 immunohistochemistry.mq.  
 7 fluorescence in situ hybridization.mq.  
 8 FISH.ti,ab.  
 9 or/4-8  
 10 human HER2 gene.gn.  
 11 Her2.ti,ab.  
 12 HER2.ti,ab.  
 13 or/10-12  
 14 sensitivity.ti,ab.  
 15 specificity.ti,ab.  
 16 (assess$ adj5 status).ti,ab.  
 17 (determin$ adj5 overexpression).ti,ab.  
 18 (determin$ adj5 status).ti,ab.  
 19 (determin$ adj5 amplification).ti,ab.  
 20 (detect$ adj5 status).ti,ab.  
 21 (detect$ adj5 amplification).ti,ab.  
 22 (evaluation adj5 status).ti,ab.  
 23 (evaluation adj5 method$).ti,ab.  
 24 (assay adj method$).ti,ab.  
 25 (quality adj control).ti,ab.  
 26 validity.ti,ab.  
 27 (reproducibility adj5 (result$ or test$)).ti,ab.  
 28 concordan$.ti,ab.  
 29 discordan$.ti,ab.  
 30 correspond$.ti,ab.  
 31 or/14-30  
 32 9 and 13  
 33 3 and 32  
 34 31 and 33  
 35 (letter or editorial or case reports).pt.  
 36 meeting.pt.  
 37 meeting abstract.mi,lt.  
 38 meeting poster.mi,lt.  
 39 or/35-38  
 40 34 not 39  
 41 urology.mc.  
 42 urinary system.mc.  
 43 respiratory system.mc.  
 44 gastroenterology.mc.  
 45 or/41-44  
 46 40 not 45  
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Search strategy for Pascal Biomed 
Date: 2007-01-26 
Database: Pascal Biomed <2001 to December 2006> 
Provider: Ovid 
 1 breast tumor.de.  
 2 breast cancer.de.  
 3 breast carcinoma.de.  
 4 (breast adj4 (cancer$ or carcinoma$ or tum?r$ or malignant$ or neo-
plasm$)).ti,ab.  
 5 or/1-4  
 6 IHC.ti,ab.  
 7 immunohistochemi$.ti,ab.  
 8 FISH.ti,ab.  
 9 fluorescence in situ hybridization.de.  
 10 or/6-9  
 11 erbB2 gene.de.  
 12 Her2.ti,ab.  
 13 HER2.ti,ab.  
 14 or/11-13  
 15 sensitivity.ti,ab.  
 16 specificity.ti,ab.  
 17 (assess$ adj5 status).ti,ab.  
 18 (determin$ adj5 amplification).ti,ab.  
 19 (determin$ adj5 overexpression).ti,ab.  
 20 (determin$ adj5 status).ti,ab.  
 21 (detect$ adj5 status).ti,ab.  
 22 (detect$ adj5 amplification).ti,ab.  
 23 (evaluation adj5 status).ti,ab.  
 24 (evaluation adj5 method$).ti,ab.  
 25 assay$.ti,ab.  
 26 (quality adj control).ti,ab.  
 27 reproducibility.de.  
 28 validity.ti,ab.  
 29 concordan$.ti,ab.  
 30 discordan$.ti,ab.  
 31 correspond$.ti,ab.  
 32 or/15-31  
 33 10 and 14  
 34 5 and 33  
 35 32 and 34  
 36 correspondence, letters.mt.  
 37 case report, clinical case.mt.  
 38 editorial.mt.  
 39 conference meeting.lt.  
 40 or/36-39  
 41 35 not 40  
 42 urology.de.  
 43 stomach.de.  
 44 lung.de.  
 45 prostate.de.  
 46 or/42-45  
 47 41 not 46  
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Glossary 
ACIS....................Automated Cellular Imaging System 
ARR ....................Absolute Risk Reduction 
CISH ...................Chromogenic In Situ Hybridization 
DCIS ...................Ductal Carcinoma In Situ  
EMEA .................European Agency for the Evaluation of Medicinal Products 
FISH ...................Fluorescence In Situ Hybridization 
HER2 ..................Human Epidermal growth Factor Receptor 2 
HUGO.................Human Genome Organisation  
IHC .....................Immuno Histo Chremistry  
LCIS....................Lobular Carcinoma In Situ 
Polysomy ............having one or a few chromosomes present in a greater 
number than is characteristic of the rest of the chromosome 
complement 
PCR.....................Polymerase Chain Reaction 
PPV .....................Positive Predictive Values 
SBR .....................Scarff-Bloom-Richardson grading 
TMA....................Tissue Micro Array 
 
 
 
